<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2508210984
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TIVICAY 50 mg Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOLUTEGRAVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2239.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Delpharm Pozna&#x144; Sp&#xF3;&#x142;ka Akcyjna" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Delpharm Poznań Spółka Akcyjna
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AX12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tivicay contains the active ingredient dolutegravir. Dolutegravir belongs to a group of anti-retroviral medicines called <em>integrase inhibitors (INIs)</em>.</p><p>Tivicay is used to treat<strong> HIV (human immunodeficiency virus) infection</strong> in adults and adolescents above 12 years of age.</p><p>Tivicay does not cure HIV infection; it reduces the amount of virus in your body and keeps it at a low level. As a result of that, it also increases the CD4 cell count in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.</p><p>Not everyone responds to treatment with Tivicay in the same way. Your doctor will monitor the effectiveness of your treatment.</p><p>Tivicay is always used in combination with other anti-retroviral medicines (<em>combination therapy</em>). To control your HIV infection, and to stop your illness from getting worse, you must keep taking all your medicines, unless your doctor tells you to stop taking any.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take Tivicay:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a9611755-fa24-4851-9dd8-ab9956a2981c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><ul><li>if you are allergic to dolutegravir or any of the other ingredients of this medicine (listed in section 6).</li><li>if you are taking another medicine called fampridine (also known as dalfampridine; used in multiple sclerosis).</li></ul><p>&reg; If you think any of these apply to you, tell your doctor.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d1ea2436-25cc-4193-931c-e53631f9c4f9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><u>Look out for important symptoms</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ff79a353-3a21-4923-8b60-5bc8cd864156 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>Some people taking medicines for HIV infection develop other conditions, which can be serious. These include:<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_318b5449-cf52-4544-82d2-68a91a132a5b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><ul><li>symptoms of infections and inflammation</li><li>joint pain, stiffness and bone problems</li></ul><p>You need to know about important signs and symptoms to look out for while you are taking Tivicay.<!--[if supportFields]><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c6b6b353-e07d-44e0-b976-0cd511bde521 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&reg; <strong>Read the information in Section 4 of this leaflet.</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f5092f31-e313-46fd-af11-8974e7410e6d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&nbsp;</p><p><strong>Other medicines and Tivicay</strong></p><p>Tell your doctor if you are taking, have recently taken or are planning to take any other medicines.</p><p>Don&#39;t take Tivicay with the following medicine:</p><ul><li>fampridine (also known as dalfampridine), used in <strong>multiple sclerosis.</strong></li></ul><p>Some medicines can affect how Tivicay works, or make it more likely that you will have side effects. Tivicay can also affect how some other medicines work.</p><p><strong>Tell your doctor</strong> if you are taking any of the medicines <em>in the following list</em>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metformin, to treat <strong>diabetes</strong></p><ul><li>medicines called <strong>antacids</strong>, to treat <strong>indigestion</strong> and <strong>heartburn. Do not take an antacid </strong>during the 6 hours before you take Tivicay, or for at least 2&nbsp;hours after you take it. (<em>See also Section&nbsp;3).</em></li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcium supplements, iron supplements and multivitamins.&nbsp; <strong>Do not take a calcium supplement, iron supplement or multivitamin </strong>during the 6 hours before you take Tivicay, or for at least 2&nbsp;hours after you take it <em>(see also Section 3).</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; etravirine, efavirenz, fosamprenavir/ritonavir, nevirapine or tipranavir/ritonavir, to treat <strong>HIV infection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, to treat tuberculosis (TB) and other <strong>bacterial infections</strong></p><ul><li>phenytoin and phenobarbital, to treat <strong>epilepsy</strong></li><li>oxcarbazepine and carbamazepine, to treat <strong>epilepsy</strong> or <strong>bipolar disorder</strong></li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>St. John&rsquo;s wort</strong> (<em>Hypericum perforatum</em>), a herbal remedy to treat <strong>depression</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg; <strong>Tell your doctor or pharmacist</strong> if you are taking any of these. Your doctor may decide to adjust your dose or that you need extra check-ups.</p><p>&nbsp;</p><p><strong>Pregnancy</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_40bf9bc1-6091-4066-a233-86a37ec75f7c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you are pregnant, think you may be pregnant, or if you are planning to have a baby:<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d8f1466c-43a5-4005-8e6e-5e34b806f64b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&reg;</strong><strong> Talk to your doctor </strong>about the risks and benefits of taking Tivicay.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_029c924f-4a99-4adc-989c-2a2a5e7b7f6b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Taking Tivicay at the time of becoming pregnant or during the first six weeks of pregnancy, may increase the risk of a type of birth defect, called neural tube defect, such as spina bifida (malformed spinal cord).</p><p>If you could get pregnant while receiving Tivicay:</p><p><strong>&reg;</strong><strong> Talk to your doctor</strong> and discuss whether there is a need for contraception, such as condom or pills.</p><p>Tell your doctor immediately if you become pregnant or are planning to become pregnant. Your doctor will review your treatment. Do not stop taking Tivicay without consulting your doctor, as this may harm you and your unborn child.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_46d74af4-96f8-4a97-8b4c-e0aa5888ed8f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Breast-feeding is <strong>not recommended</strong> in women living with HIV because HIV infection can be passed on to the baby in breast milk.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_a229587d-96d9-4bec-b14f-5972a65c4f62 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>A small amount of the ingredients in Tivicay can pass into your breast milk.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5d30bbf8-2d20-488b-9044-59bf7e7a2abd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>If you are breast-feeding, or thinking about breast-feeding, you should <strong>discuss it with your doctor as soon as possible</strong>.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8422bbbe-17a6-4d64-874c-1c60810cc492 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Driving and using machines</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ee3b99d1-8718-4e50-b737-605f57b89e2e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Tivicay can make you dizzy and have other side effects that make you less alert.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg; Don&rsquo;t drive or operate machinery unless you are sure you&rsquo;re not affected.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_575ddf85-156e-4f67-bad3-4454f13aa0ea \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Tivicay contains less than 1 mmol sodium (23 mg) per tablet</strong>, that is to say is essentially &lsquo;sodium-free.&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><ul><li>The usual dose is 50&nbsp;mg <strong>once a day.</strong></li><li>If you are taking certain <strong>other medicines</strong>, the dose is 50&nbsp;mg <strong>twice a day.</strong></li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>For HIV that is resistant</strong> to other medicines similar to Tivicay, the usual is 50&nbsp;mg, <strong>twice a day</strong>.</p><p>Your doctor will decide on the correct dose of Tivicay for you.</p><p>Swallow the tablet(s) with some liquid.&nbsp;</p><p>Tivicay can be taken with or without food. When Tivicay is taken twice a day, your doctor may advise you to take with food.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><ul><li>Children and adolescents weighing at least 20&nbsp;kg can take the adult dose of 50&nbsp;mg, once a day. Your doctor will decide how Tivicay should be given.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tivicay should not be used in children and adolescents with <strong>HIV infection that is resistant</strong> to other medicines similar to Tivicay.</p><p>&nbsp;</p><p><u>Antacid medicines</u></p><p>Antacids, to treat indigestion and heartburn, can stop Tivicay being absorbed into your body and make it less effective.</p><p>Do not take an antacid during the 6 hours before you take Tivicay, or for at least 2 hours after you take it.&nbsp; Other acid-lowering medicines like ranitidine and omeprazole can be taken at the same time as Tivicay.&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg; Talk to your doctor for further advice on taking acid-lowering medicines with Tivicay.</p><p>&nbsp;</p><p><u>Calcium supplements, iron supplements or multivitamins</u></p><p>Calcium supplements, iron supplements or multivitamins can stop Tivicay being absorbed into your body and make it less effective.</p><p>Do not take a calcium supplement, iron supplement or multivitamin during the 6 hours before you take Tivicay, or for at least 2 hours after you take it.&nbsp;</p><p>&reg; Talk to your doctor for further advice on taking calcium supplements, iron supplements or multivitamins with Tivicay.</p><p>&nbsp;</p><p><strong>If you take more Tivicay than you should</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_303b206c-f0fd-4cab-a59a-00b45774a695 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you take too many tablets of Tivicay, <strong>contact your doctor or pharmacist for advice</strong>. If possible, show them the Tivicay pack.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Tivicay</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e0f78317-f5dc-412e-85ff-02912eda71f5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you miss a dose, take it as soon as you remember. But if your next dose is due within 4 hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&reg; <strong>Don&#39;t take a double dose </strong>to make up for a missed dose.</p><p>&nbsp;</p><p><strong>Don&rsquo;t stop taking Tivicay without advice from your doctor</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_72077b07-5526-4a23-b034-89aab0c74ddd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Take Tivicay for as long as your doctor recommends. Don&rsquo;t stop unless your doctor advises you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, but not everybody gets them.</p><p>&nbsp;</p><p><strong>Allergic reactions</strong></p><p>These are uncommon in people taking Tivicay. Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp; a high temperature (<em>fever</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; lack of energy (<em>fatigue</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or mouth (<em>angioedema</em>), causing difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle or joint aches.</p><p><strong>&reg;</strong><strong> </strong><strong>See a doctor straight away. </strong>Your doctor may decide to carry out tests on your liver, kidneys or blood, and may tell you to stop taking Tivicay.</p><p><strong>&nbsp;</strong></p><p><strong>Very common side effects</strong></p><p>These may affect <strong>more than 1 in 10 people</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea</em>).</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10</strong> <strong>people</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp; itching (<em>pruritus</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; being sick (<em>vomiting</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach pain (<em>abdominal pain</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach (<em>abdominal</em>) discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp; insomnia</p><p>&middot;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp; abnormal dreams</p><p>&middot;&nbsp;&nbsp;&nbsp; depression (feelings of deep sadness and unworthiness)</p><p>&middot;&nbsp;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp; lack of energy (<em>fatigue</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; wind (<em>flatulence</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; increase in the level of liver enzymes</p><p>&middot;&nbsp;&nbsp;&nbsp; increase in the level of enzymes produced in the muscles (<em>creatine phosphokinase</em>).</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p>These may affect <strong>up to 1 in 100 people</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp; inflammation of the liver (<em>hepatitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; suicide attempt*</p><p>&middot;&nbsp;&nbsp;&nbsp; suicidal thoughts*</p><p>&middot;&nbsp;&nbsp;&nbsp; panic attack</p><p>&middot;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle pain</p><p><strong>* particularly in patients who have had depression or mental health problems before</strong></p><p><strong>&nbsp;</strong></p><p><strong>Rare side effects</strong></p><p>These may affect <strong>up to 1 in 1000 people</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp; liver failure (signs may include yellowing of the skin and the whites of the eyes or unusually dark urine)</p><p>&middot;&nbsp;&nbsp;&nbsp; increase in bilirubin (a test of liver function) in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp; suicide (particularly in patients who have had depression or mental health problems before)</p><p>&reg;<strong> </strong><strong>&nbsp;Tell your doctor immediately</strong> if you experience any mental health problems (see also other mental health problems above).</p><p><strong>&nbsp;</strong></p><p><strong>Symptoms of infection and inflammation </strong></p><p>People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (<em>opportunistic infections</em>). Such infections may have been &ldquo;silent&rdquo; and not detected by the weak immune system before treatment was started. After starting treatment, the immune system becomes stronger, and may attack the infections, which can cause symptoms of infection or inflammation. Symptoms usually include <strong>fever</strong>, plus some of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach ache</p><p>&middot;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (<em>autoimmune disorders</em>).&nbsp; The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. Symptoms may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations (rapid or irregular heartbeat) or tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperactivity (excessive restlessness and movement)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness beginning in the hands and feet and moving up towards the trunk of the body.</p><p><strong>If you get any symptoms of infection</strong> and inflammation or if you notice any of the symptoms above:</p><p><strong>&reg;</strong><strong> </strong><strong>Tell your doctor immediately</strong>. Don&rsquo;t take other medicines for the infection without your doctor&rsquo;s advice.</p><p>&nbsp;</p><p><strong>Joint pain, stiffness and bone problems</strong></p><p>Some people taking combination therapy for HIV develop a condition called <em>osteonecrosis</em>. With this condition, parts of the bone tissue die because of reduced blood supply to the bone. People may be more likely to get this condition:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they have been taking combination therapy for a long time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are also taking anti-inflammatory medicines called corticosteroids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they drink alcohol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if their immune systems are very weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are overweight.</p><p><strong>Signs of osteonecrosis include:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness in the joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aches and pains in the joints (especially in the hip, knee or shoulder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty moving.</p><p>If you notice any of these symptoms:</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&reg;</strong><strong> </strong><strong>Tell your doctor</strong>.</p><p>&nbsp;</p><p><strong>Weight, blood lipid and blood glucose effects</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_95db552b-7d3f-40ba-8fb9-4192fcccd23e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and lifestyle, and sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated after EXP on the carton and bottle.</p><p>Do not store above 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The active substance is dolutegravir. Each tablet contains dolutegravir sodium equivalent to 50&nbsp;mg dolutegravir.</p><p>-&nbsp; &nbsp; &nbsp;The other ingredients are:</p><p><u>Tablet Core:</u></p><p>D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, sodium stearyl fumarate</p><p><u>Tablet coating:</u></p><p>Poly(vinyl alcohol) partially hydrolyzed, titanium dioxide, macrogol/PEG, talc, iron oxide yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	TIVICAY tablets are supplied in HDPE (high density polyethylene) bottles of 30 tablets.
	The 50 mg tablets are yellow, round, biconvex tablets debossed with ‘SV 572’ on one side and ‘50’ on the other side.
	
	Not all pack sizes may be available in your country. 
	
TIVICAY is a trademark owned by or licensed to the ViiV Healthcare group of companies.
© 2024 ViiV Healthcare group of companies, all rights reserved.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c98ca129-c896-4a35-a652-94f217b82462 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland<!--[if supportFields]><span
style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
color:#242424;background:white'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_cce07a64-a6b2-4261-9fa0-04a74a6b1842 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
color:#242424;background:white'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Marketing Authorization Holder<!--[if supportFields]><span style='font-size:11.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d5509986-b08a-4a68-a4fd-ee37c9c5dbdd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia</p><p>*member of the GlaxoSmithKline group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: UK-v27
This leaflet was last revised on 05 June 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي تيڤيكاي على المكوّن الفعَّال دولوتيجراڤير. ينتمي دولوتيجراڤير إلى فئة من مضادات الفيروسات الرجعية تُسمى <em>مثبطات الانتيغراز</em> <em>(INIs)</em>.</p><p dir="RTL">يستخدم تيڤيكاي في علاج <strong>عدوى الإيدز (فيروس نقص المناعة البشرية)</strong> لدى البالغين والمراهقين فوق 12 سنة.</p><p dir="RTL">إن تيڤيكاي لا يُشفي من مرض نقص المناعة البشرية، وإنما يقلل من انتشار الفيروس في الجسم ويبقيه في مستوى منخفض. وكنتيجة لذلك، يعمل أيضًا على زيادة عدد خلايا CD4 (كتلة التمايز 4) في الدم. وخلايا CD4 (كتلة التمايز 4) هي نوع من خلايا الدم البيضاء التي لها دور مهم في مساعدة الجسم على مكافحة العدوى.</p><p dir="RTL">وتختلف كيفية استجابة المرضى للعلاج بتيڤيكاي. سوف يراقب الطبيب مدى فعالية العلاج لديك.</p><p dir="RTL">يُستخدم تيڤيكاي دائمًا بالتزامن مع الأدوية الأخرى المضادة للفيروسات الرجعية (<em>علاج مُرَكّب</em>). ويجب الاستمرار في تناول جميع الأدوية للسيطرة على عدوى فيروس نقص المناعة البشرية ولمنع تفاقم المرض، ما لم ينصحك طبيبك بالتوقف عن تناول أيّ من الأدوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول تيڤيكاي:</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-begin'></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>VAULT_ND_f318e8d5-6a99-4789-bc2c-6f2c96ae59b6 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><ul><li dir="RTL">إذا كانت لديك حساسية من دولوتيجراڤير أو أي من المكوّنات الأخرى لهذا الدواء (المذكورة في القسم 6).</li><li dir="RTL">إذا كنت تتناول دواءً آخر يُسمى فامبريدين (ويُعرَف أيضًا باسم دالفامبريدين )، المستخدم لعلاج حالات التصلب المتعدد.</li></ul><p dir="RTL">&not; أخبر طبيبك إذا كنت تعتقد أن أي من هذه الحالات تنطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-begin'></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>VAULT_ND_31aca68f-060b-4494-989d-25fdd0ed6b57 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><u>انتبه للأعراض الخطيرة</u><!--[if supportFields]><u><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-begin'></span> </span></u><u><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>DOCVARIABLE</span></u><span dir=RTL></span><span
dir=RTL></span><u><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> </span></u><u><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>VAULT_ND_821f001d-4ea3-4797-bc5c-a102131b92b4 \*
MERGEFORMAT</span></u><span dir=RTL></span><span dir=RTL></span><u><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-end'></span></span></u><![endif]--></p><p dir="RTL">قد تتطور لدى بعض الأشخاص الذين يتناولون أدوية لعلاج عدوى الإيدز (فيروس نقص المناعة البشرية) بعض الحالات الأخرى التي قد تكون خطيرة. ويشمل ذلك ما يلي:<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_0aa69abc-a11c-41a6-86cf-a7f2fb4cca93 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><ul><li dir="RTL">أعراض العدوى والالتهاب</li><li dir="RTL">آلام وتيبس المفاصل ومشكلات العظام</li></ul><p dir="RTL">يجب عليك معرفة العلامات والأعراض المهمة التي يجب الحذر منها أثناء تناول تيڤيكاي.<!--[if supportFields]><span lang=AR-EG
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>VAULT_ND_5489866c-52ca-4f1e-adc3-e9ded6cf8412 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&not;</strong><strong> ​اقرأ المعلومات الخاصة في القسم 4 من هذه النشرة​.</strong><!--[if supportFields]><b><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-begin'></span> </span></b><b><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>VAULT_ND_ded52651-f222-47a7-a6cb-f43bd6ba2011 \*
MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وتيڤيكاي</strong></p><p dir="RTL">أخبر الطبيب إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخرًا أو تنوي تناول أدوية أخرى.</p><p dir="RTL">​لا تتناول تيڤيكاي مع هذه الأدوية:​</p><ul><li dir="RTL">فامبريدين (ويُعرَف أيضًا باسم دالفامبريدين ) ،المستخدم لعلاج حالات التصلب المتعدد</li></ul><p dir="RTL">قد تؤثر بعض الأدوية على فاعلية علاج تيڤيكاي للمرض أو يمكن أن تزيد من احتمال التعرّض للآثار الجانبية. كما قد يؤثر تيڤيكاي على فاعلية بعض الأدوية الأخرى.</p><p dir="RTL"><strong>يجب إبلاغ الطبيب</strong> في حالة تناول أيّ من الأدوية المذكورة <em>في القائمة التالية</em>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتفورمين لعلاج <strong>السكري</strong></p><ul><li dir="RTL">الأدوية المعروفة باسم <strong>مضادات الحموضة</strong> لعلاج <strong>عسر الهضم</strong> و<strong>الحموضة المعوية</strong>. <strong>لا تتناول دواءً مضادًا للحموضة</strong> خلال الست ساعات التي تسبق تناول تيڤيكاي وخلال ساعتين على الأقل من تناوله. (<em>انظر أيضًا القسم 3</em>).</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات الكالسيوم ومكملات الحديد والمكملات متعددة الفيتامينات. <strong>لا تتناول مكملات الكالسيوم أو مكملات الحديد أو المكملات متعددة الفيتامينات</strong> خلال الست ساعات التي تسبق تناول تيڤيكاي وخلال ساعتين على الأقل من تناوله (<em>انظر أيضًا القسم 3</em>).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إتراڤيرين أو إيفاڤيرينز أو فوسامبريناڤير/ريتوناڤير أو نيڤيرابين أو تبراناڤير/ريتوناڤير لعلاج <strong>عدوى نقص المناعة البشرية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين لعلاج السل وغيره من <strong>أمراض</strong> <strong>العدوى البكتيرية</strong></p><ul><li dir="RTL">فينيتوين وفينوباربيتال لعلاج <strong>الصرع</strong></li><li dir="RTL">أوكسكاربازيبين وكاربامازيبين لعلاج <strong>الصرع</strong> أو <strong>الاضطراب ثنائي القطب</strong></li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نبتة سانت جونز</strong> (<em>العرن المثقوب</em>)، وهو علاج عشبي لعلاج <strong>الاكتئاب</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; <strong>ينبغي إخبار الطبيب أو الصيدلي</strong> إذا كنت تتناول أيًا من هذه الأدوية. قد يقرر طبيبك تعديل الجرعة أو حاجتك إلى إجراء المزيد من الفحوصات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-begin'></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>VAULT_ND_e311bd58-a8eb-4976-9161-1c132725240d \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا &rlm;‫كنتِ حاملاً أو تفكرين في الحمل أو إذا كنتِ تخططين للإنجاب:<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_5773b388-a028-4e09-8360-403bfc3d2817 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&not;</strong> ​<strong>تحدثي مع طبيبكِ</strong> حول مخاطر وفوائد تناول تيڤيكاي.<!--[if supportFields]><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'>VAULT_ND_c939375c-f0e1-460a-88ab-dac7aa2eace9
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-end'></span></span><![endif]--></p><p dir="RTL">إن تناول تيڤيكاي أثناء الحمل أو خلال الأسابيع الستة الأولى من الحمل قد يزيد من خطر حدوث عيب خلقي للجنين، يسمى عيب الأنبوب العصبي، مثل السنسنة المشقوقة (تشوه الحبل الشوكي).<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_9456d130-4fb9-48a4-95f4-6a479d45e0ac
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">في حالة احتمالية حدوث حمل أثناء تلقي العلاج بتيڤيكاي:<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_1976daf7-dfa3-4c28-ba2e-c8bcc73c5630
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&not;</strong> ​<strong>تحدثي مع طبيبكِ </strong>وناقشي معه أهمية استخدام وسائل منع الحمل، مثل الواقي الذكري أو الحبوب.<!--[if supportFields]><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_1710570a-902a-414c-b2c7-cd34312b9a2d
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">أخبري الطبيب على الفور في حالة حدوث حمل أو كنتِ تنوين الإنجاب. وسيراجع معكِ الطبيب علاجكِ. لا تتوقفي عن تناول تيڤيكاي دون استشارة طبيبكِ، لأن هذا قد يضر بكِ وبالجنين.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_34b4fcb1-5635-4fd7-a618-5c71de11bcb6
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الرضاعة الطبيعية</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-begin'></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>VAULT_ND_d20f6d80-181e-48a7-87f2-331e60d353ec \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>لا ينصح بالرضاعة الطبيعية</strong> لدى النساء المتعايشات مع مرض نقص المناعة البشرية ، لأن عدوى فيروس نقص المناعة البشرية يمكنها الانتقال إلى الطفل عبر لبن الأم.<!--[if supportFields]><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>VAULT_ND_22c61546-ad66-4c15-90bd-ec1121930fd2 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-end'></span></span><![endif]--></p><p dir="RTL">قد ينتقل جزء ضئيل من مكونات تيفيكاي إلى حليب الثدي.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_290d6cd4-959f-4304-b295-61bf3bfc6136
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">إذا كنتِ ترضعين طفلكِ رضاعة طبيعية أو تفكرين في ذلك ،<!--[if supportFields]><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>VAULT_ND_45558cd2-be7e-4520-a338-d95c4f52c6fb \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-end'></span></span><![endif]-->يجب عليك <strong>مناقشة </strong>هذا الأمر مع <strong>طبيبكِ </strong><strong>في أقرب وقت ممكن</strong>.</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-begin'></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>VAULT_ND_444d7e81-1af1-4083-bbf2-8e34e688867b \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن أن يصيبك تيڤيكاي بالدوار وغيره من الأعراض الجانبية التي تجعلك أقل انتباهًا.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; تجنب القيادة أو تشغيل الآلات ما لم تتأكد من عدم تأثرك.<!--[if supportFields]><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'>VAULT_ND_7d7dc4f2-944f-47e2-af8a-557ce5a28edb \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي تيفيكاي على أقل من واحد ملي مول من الصوديوم (23 ملجم) لكل قرص</strong>، مما يعني أنه في الأساس &quot;خالي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب الالتزام بدقة بتعليمات الطبيب بشأن طريقة تناول هذا الدواء. راجع طبيبك أو الصيدلي في حالة عدم التأكد بشأن طريقة الاستعمال.</p><ul><li dir="RTL">الجرعة المعتادة هي 50 ملجم <strong>مرة واحدة في اليوم.</strong></li><li dir="RTL">إذا كنت تتناول <strong>أدوية أخرى</strong> معينة ، تكون الجرعة هي 50 ملجم <strong>مرتين في اليوم.</strong></li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لفيروس نقص المناعة البشرية</strong> <strong>المقاوم</strong> للأدوية الأخرى المشابهة لتيڤيكاي، تكون الجرعة المعتادة 50 ملجم <strong>مرتين في اليوم</strong>.</p><p dir="RTL">سوف يحدد الطبيب جرعة تيڤيكاي المناسبة لك.</p><p dir="RTL">ابتلع القرص أو الأقراص مع كمية من السوائل.</p><p dir="RTL">يمكن تناول تيڤيكاي مع الطعام أو بدونه. عند تناول تيڤيكاي مرتين في اليوم، قد ينصحك الطبيب بتناوله مع الطعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع الأطفال والمراهقين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن للأطفال والمراهقين الذين يزنون 20 كجم على الأقل أخذ جرعة البالغين، والتي تُقدر 50 ملجم مرة واحدة في اليوم. سوف يحدد الطبيب طريقة تناول تيڤيكاي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام تيڤيكاي في الأطفال والمراهقين المصابين <strong>بعدوى فيروس نقص المناعة البشرية المقاومة</strong> لأدوية أخرى مشابهة لتيڤيكاي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مضادات الحموضة</u></p><p dir="RTL">يمكن أن تعوق مضادات الحموضة، التي تُستخدم لعلاج عسر الهضم والحموضة المعوية، امتصاص تيڤيكاي في الجسم وتحدّ من فعاليته.</p><p dir="RTL">لا تتناول دواءً مضادًا للحموضة خلال الست ساعات التي تسبق تناول تيڤيكاي وخلال ساعتين على الأقل من تناوله. يمكن تناول الأدوية الأخرى التي تقلل الحموضة، مثل الرانيتيدين والأوميبرازول في نفس الوقت مع تيڤيكاي.&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; استشر الطبيب للحصول على المشورة بشأن تناول الأدوية التي تقلل الحموضة مع تيڤيكاي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مكملات الكالسيوم أو مكملات الحديد أو المكملات متعددة الفيتامينات</u></p><p dir="RTL">يمكن أن تعوق مكملات الكالسيوم أو مكملات الحديد أو المكملات متعددة الفيتامينات من امتصاص تيڤيكاي في الجسم وتحدّ من فعاليته.</p><p dir="RTL">لا تأخذ مكملات الكالسيوم أو مكملات الحديد أو المكملات متعددة الفيتامينات خلال الست ساعات التي تسبق تناول تيڤيكاي وخلال ساعتين على الأقل من تناوله.&nbsp;</p><p dir="RTL">&not; استشر الطبيب للحصول على المشورة بشأن تناول مكملات الكالسيوم أو مكملات الحديد أو المكملات متعددة الفيتامينات مع تيڤيكاي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة تيڤيكاي زائدة عن ما ينبغي تناوله</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-begin'></span> </span></b><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> </span></b><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG;mso-bidi-font-weight:bold'>VAULT_ND_5d66ca02-c17a-40f8-8fb5-a65a4ff74c3d
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">عند تناول عدد من أقراص تيڤيكاي أكثر من اللازم، <strong>استشر الطبيب أو الصيدلاني</strong>. ويُفضل أن تريهم عبوة تيڤيكاي إن أمكن.​</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان تناول تيڤيكاي</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-begin'></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG;mso-bidi-font-weight:
bold'>VAULT_ND_21fe3dab-015e-4195-9b35-e2f6ab3c4f38 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا فاتتك جرعة، تناولها فور تذكرها. لكن إذا كان موعد الجرعة التالية يحل خلال 4 ساعات، فاقتصر على تناول الجرعة التالية في موعدها المحدد. ثم أكمل العلاج كما في السابق.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; <strong>​</strong><strong>لا تتناول ​جرعة​ مضاعفة</strong> لتعويض الجرعة التي فاتتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتوقف عن تناول تيڤيكاي دون استشارة طبيبك</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-begin'></span> </span></b><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> </span></b><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG;mso-bidi-font-weight:bold'>VAULT_ND_889452aa-db88-4218-b7c7-f118d3051f52
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">تناول تيڤيكاي للمدة التي أوصى بها الطبيب. ويجب عدم التوقف عن تناول الدواء إلا إذا أوصى الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استعمال هذا الدواء، يمكنك سؤال الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب هذا الدواء، مثل جميع الأدوية، في حدوث آثار جانبية، ولكن ليس بالضرورة أن يصاب بها جميع الأشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية</strong></p><p dir="RTL">غير شائعة لدى المرضى الذين يستخدمون تيڤيكاي. تشمل العلامات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة (<em>الحمى</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; فقدان الطاقة (<em>التعب</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ​حدوث تورم في بعض الأحيان للوجه والفم (<em>​</em><em>وذمة وعائية</em><em>​</em>) مما ينتج عنه صعوبة في التنفس​</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في العضلات أو المفاصل</p><p dir="RTL"><strong>&not;</strong> <strong>استشر الطبيب على الفور.</strong> قد يقرر طبيبك إجراء اختبارات على الكبد أو الكليتين أو الدم، وقد يطلب منك التوقف عن<br />تناول تيڤيكاي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا </strong></p><p dir="RTL">قد تصيب <strong>أكثر من شخص واحد من كل 10 أشخاص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; شعور بالتوعك (<em>غثيان</em>)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة </strong></p><p dir="RTL">قد تؤثر على <strong>ما يصل إلى 1 من كل 10 أشخاص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; حكة (<em>حكة جلدية</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إعياء (<em>قيء</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في المعدة (<em>ألم في البطن</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مغص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; أرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; أحلام مزعجة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اكتئاب (شعور بالحزن الشديد وعدم الجدارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; قلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; فقدان الطاقة (<em>التعب</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ريح (<em>انتفاخ بسبب الغازات</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ​زيادة في مستوى إنزيمات الكبد​</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; زيادة في مستوى الإنزيمات التي يتم إنتاجها في العضلات (<em>فسفوكيناز الكرياتين</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة </strong></p><p dir="RTL">قد تؤثر على <strong>ما يصل إلى 1 من كل 100 شخص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التهاب الكبد (<em>التهاب الكبد الوبائي</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; محاولات انتحار*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; أفكار انتحارية*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; نوبات الهلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL"><strong>*بشكل خاص لدى الأشخاص الذين يعانون من الإكتئاب ومن مشاكل في الصحة النفسية سابقاً</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong></p><p dir="RTL">قد تؤثر على <strong>ما يصل إلى 1 من كل 1000 شخص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كبدي (قد تشمل الأعراض اصفرار الجلد وابيضاض العينين أو بول داكن بشكل غير اعتيادي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة البيليروبين (اختبار وظائف الكبد) في الدم.</p><ul><li dir="RTL">الانتحار (لاسيما لدى المرضى الذين عانوا من من قبل من نوبات الاكتئاب أو مشاكل في الصحة العقلية)</li></ul><p dir="RTL"><strong>&ccedil;</strong><strong> أخبر طبيبك على الفور </strong>إذا كنت تعاني من أي مشاكل في الصحة العقلية (انظر أيضًا مشاكل الصحة العقلية الأخرى سالفة الذكر).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض العدوى والالتهاب </strong></p><p dir="RTL">يعاني المرضى المصابون بحالة متقدمة من عدوى نقص المناعة البشرية (الإيدز) من ضعف الجهاز المناعي ويصبحون أكثر عرضة للإصابة بعدوى خطيرة (<em>عدوى انتهازية</em>). قد لا تعلن هذه العدوى عن نفسها ولا تُظهر أي أعراض، وبالتالي لن يكتشفها الجهاز المناعي الضعيف قبل بدء العلاج. بعد بدء العلاج، يصبح الجهاز المناعي أكثر قوة، ويهاجم العدوى، مما يؤدي إلى ظهور أعراض العدوى أو الالتهاب. عادة ما تشمل الأعراض <strong>​</strong><strong>الحمى</strong>​، بالإضافة إلى بعض من الأعراض التالية:​</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">​في حالات نادرة، بمجرد أن يصبح الجهاز المناعي أكثر قوة، قد يهاجم أنسجة الجسم السليمة (​<em>اضطرابات المناعة الذاتية</em><em>​</em>). وربما تظهر أعراض اضطرابات المناعة الذاتية بعد أشهر من تناول الدواء لعلاج عدوى فيروس نقص المناعة البشرية. قد تشمل الأعراض:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان القلب (ضربات قلب سريعة أو غير منتظمة) أو الارتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحركة (التململ والحركة الزائدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف يبدأ في اليدين والقدمين وينتقل لأعلى البدن.</p><p dir="RTL"><strong>إذا كنت تعاني أي من أعراض العدوى </strong>والإلتهاب، أو لاحظت أي من الأعراض المذكورة أعلاه:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; <strong>&not;</strong> <strong>يجب إبلاغ الطبيب على الفور</strong>. ولا تتناول أي أدوية أخرى لعلاج العدوى بدون استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آلام وتيبس المفاصل ومشكلات العظام</strong></p><p dir="RTL">​يظهر لدى بعض الأشخاص الذين يتناولون العلاج المركب لفيروس نقص المناعة البشرية حالة يُطلق عليها <em>​</em><em>النخر العظمي</em><em>​</em>. في هذه الحالة، تموت أجزاء من أنسجة العظام بسبب انخفاض تدفق الدم إلى العظام. تزداد احتمالية الإصابة بهذه الحالة لدى الأشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون علاجًا مركبًا لفترة طويلة من الوقت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون الأدوية المضادة للالتهابات التي يُطلق عليها الكورتيكوستيرويدات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون مشروبات كحولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يعانون من ضعف شديد في جهازهم المناعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يعانون من زيادة الوزن.</p><p dir="RTL"><strong>تشمل علامات النخر العظمي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع وآلام في المفاصل (خاصةً في الورك أو الركبة أو الكتف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الحركة.</p><p dir="RTL">عند ملاحظة أي من هذه الأعراض:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; <strong>&not;</strong> <strong>أخبر طبيبك</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات الوزن، ودهون الدم، وجلوكوز الدم</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-EG style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span style='mso-element:
field-begin'></span> </span></b><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-EG'><span dir=RTL></span><span
dir=RTL></span> </span></b><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG;mso-bidi-font-weight:bold'>VAULT_ND_58d31c76-a64e-4361-9d2b-fde70700d5e5
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-EG style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">قد تحدث زيادة في الوزن وزيادة معدلات الدهون والجلوكوز في الدم في اثناء تناول علاج فيروس نقص المناعة البشرية. ويرتبط ذلك جزئيًا باستعادة الصحة ونمط الحياة، و أحيانًا بأدوية فيروس نقص المناعة البشرية ذاتها. سيفحص طبيبك هذه التغييرات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ الدواء بعيدًا عن نظر ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى الزجاجة بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">يجب عدم تخزينه في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">لا تتخلص من الأدوية في الفضلات السائلة ولا المخلفات المنزلية. استشر الصيدلي لديك عن كيفية التخلص من الأدوية التي لم تعد تستعملها. فهذه الإجراءات من شأنها أن تحافظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em>المادة الفعَّالة هي دولوتيجراڤير. يحتوي كل قرص على صوديوم دولوتيجراڤير يعادل 50 ملجم من الدولوتيجراڤير.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp;المكونات الأخرى هي:</p><p dir="RTL"><u>لُب القرص:</u></p><p dir="RTL">دي-مانيتول، سليلوز دقيق التبلور، بوفيدون K29/32، جلايكولات نشاء الصوديوم، فومارات ستيريل الصوديوم</p><p dir="RTL"><u>غلاف القرص:</u></p><p dir="RTL">كحول عديد الفينيل - متحلل جزئيًا، ثاني أكسيد التيتانيوم، ماكروغول/PEG، تلك، أكسيد حديد أصفر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر أقراص تيڤيكاي في قارورة من البولي إيثيلين عالي الكثافة (HDPE) وتحتوي على 30 قرصًا.</p><p dir="RTL">والأقراص صفراء مستديرة ومحدبة الوجهين مطبوع على أحد الجانبين &quot;SV 572&quot; و&quot;50&quot; على الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في بلدك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تيڤيكاي</strong> علامة تجارية مملوكة أو مرخصة لمجموعة شركات ڤيڤ هيلثكير.</p><p dir="RTL">&copy; 2024 مجموعة شركات ڤيڤ هيلثكير. جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المُصنعة:</strong></p><p dir="RTL">&nbsp;ديلفارم بوزنان أسبولكا أكسيجنا، أولي. جرانڤالسكا 189، 60 - 322 بوزنان، بولندا</p><p dir="RTL"><strong>حامل ترخيص التسويق:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة* جدة، المملكة العربية السعودية</p><p dir="RTL">العنوان: صندوق بريد 22617 ، جدة 21416 ، المملكة العربية السعودية.</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم إصدار المملكة المتحدة: UK-v27
تمت آخر مراجعة لهذه النشرة في  5 يونيو 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tivicay 50 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Yellow, round, biconvex tablets debossed with ‘SV 572’ on one side and ‘50’ on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tivicay should be prescribed by physicians experienced in the management of HIV infection.</p><p><u>Posology</u></p><p><em>Adults</em></p><p><em>Patients infected with HIV-1 without documented or clinically suspected resistance to the integrase class</em></p><p>The recommended dose of dolutegravir is 50&nbsp;mg orally once daily.</p><p>Dolutegravir should be administered twice daily in this population when co-administered with some medicines (e.g. efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin).&nbsp; Please refer to section 4.5.</p><p><em>Patients infected with HIV-1 with resistance to the integrase class (documented or clinically suspected)</em></p><p>The recommended dose of dolutegravir is 50&nbsp;mg twice daily.</p><p>In the presence of documented resistance that includes Q148 + &sup3;2 secondary mutations from G140A/C/S, E138A/K/T, L74I, modelling suggests that an increased dose may be considered for patients with limited treatment options (less than 2 active agents) due to advanced multi class resistance (see section 5.2).</p><p>The decision to use dolutegravir for such patients should be informed by the integrase resistance pattern (see section 5.1).</p><p>&nbsp;</p><p><em>Adolescents aged 12 and above to less than 18 years, and weighing at least 20 kg</em></p><p>In patients infected with HIV-1 without resistance to the integrase class, the recommended dose of dolutegravir is 50&nbsp;mg once daily. In the presence of integrase inhibitor resistance, there are insufficient data to recommend a dose for dolutegravir in adolescents.</p><p>&nbsp;</p><p><em>Missed doses</em></p><p>If the patient misses a dose of Tivicay, the patient should take Tivicay as soon as possible, providing the next dose is not due within 4 hours. If the next dose is due within 4 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>There are limited data available on the use of dolutegravir in patients aged 65 years and over.&nbsp; There is no evidence that elderly patients require a different dose than younger adult patients (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>No dosage adjustment is required in patients with mild, moderate or severe (CrCl &lt;30 mL/min, not on dialysis) renal impairment.&nbsp; No data are available in subjects receiving dialysis although differences in pharmacokinetics are not expected in this population (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>No dosage adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh grade A or B).&nbsp; No data are available in patients with severe hepatic impairment (Child-Pugh grade C); therefore dolutegravir should be used with caution in these patients (see section 5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Oral use.</p><p>Tivicay can be taken with or without food (see section 5.2). In the presence of integrase class resistance, Tivicay should preferably be taken with food to enhance exposure (particularly in patients with Q148 mutations) (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Medicinal products with narrow therapeutic windows that are substrates of organic cation transporter 2 (OCT2), including but not limited to fampridine (also known as dalfampridine; see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Integrase class resistance of particular concern</u></p><p>The decision to use dolutegravir in the presence of integrase class resistance should take into account that the activity of dolutegravir is considerably compromised for viral strains harbouring Q148+&sup3;2 secondary mutations from G140A/C/S, E138A/K/T, L74I (see section 5.1). To what extent dolutegravir provides added efficacy in the presence of such integrase class resistance is uncertain (see section 5.2).</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>Hypersensitivity reactions have been reported with dolutegravir, and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions. Dolutegravir and other suspect medicinal products should be discontinued immediately if signs or symptoms of hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by raised liver enzymes, fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, eosinophilia, angioedema). Clinical status including liver aminotransferases and bilirubin should be monitored. Delay in stopping treatment with dolutegravir or other suspect active substances after the onset of hypersensitivity may result in a life-threatening allergic reaction.</p><p>&nbsp;</p><p><u>Immune Reactivation Syndrome</u></p><p>In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and <em>Pneumocystis </em><em>jirovecii</em> pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.&nbsp; Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution, however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p>Liver biochemistry elevations consistent with immune reconstitution syndrome were observed in some hepatitis B and/or C co-infected patients at the start of dolutegravir therapy.&nbsp; Monitoring of liver biochemistries is recommended in patients with hepatitis B and/or C co-infection.&nbsp; Particular diligence should be applied in initiating or maintaining effective hepatitis B therapy (referring to treatment guidelines) when starting dolutegravir-based therapy in hepatitis B co-infected patients (see section 4.8).</p><p>&nbsp;</p><p><u>Opportunistic infections</u></p><p>Patients should be advised that dolutegravir or any other antiretroviral therapy does not cure HIV infection and that they may still develop opportunistic infections and other complications of HIV infection. Therefore, patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.</p><p><strong>&nbsp;</strong></p><p><u>Drug interactions</u></p><p>Factors that decrease dolutegravir exposure should be avoided in the presence of integrase class resistance. This includes co-administration with medicinal products that reduce dolutegravir exposure (e.g. magnesium/ aluminium-containing antacid, iron and calcium supplements, multivitamins and inducing agents, etravirine (without boosted protease inhibitors), tipranavir/ritonavir, rifampicin, St. John&rsquo;s wort and certain anti-epileptic medicinal products) (see section 4.5).</p><p>Dolutegravir increased metformin concentrations. A dose adjustment of metformin should be considered when starting and stopping coadministration of dolutegravir with metformin, to maintain glycaemic control (see section 4.5). Metformin is eliminated renally and, therefore, it is of importance to monitor renal function when co-treated with dolutegravir. This combination may increase the risk for lactic acidosis in patients with moderate renal impairment (stage 3a creatinine clearance [CrCl] 45&ndash; 59 mL/min) and a cautious approach is recommended. Reduction of the metformin dose should be highly considered.&nbsp;</p><p>&nbsp;</p><p><u>Osteonecrosis</u></p><p>Although the aetiology is considered to be multifactorial (including corticosteroid use, biphosphonates, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported in patients with advanced HIV-disease and/or long-term exposure to CART. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p>&nbsp;</p><p><u>Weight and metabolic parameters</u></p><p>An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and lifestyle. For lipids and weight, there is in some cases evidence for a treatment effect. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.</p><p>&nbsp;</p><p><u>Lamivudine and dolutegravir</u></p><p>The two-drug regimen of dolutegravir 50 mg once daily and lamivudine 300 mg once daily was explored in two large randomized and blinded studies, GEMINI 1 and GEMINI 2 (see section 5.1). This regimen is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Tivicay contains less than 1 mmol sodium (23 mg) per tablet, that is to say is essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of other agents on the pharmacokinetics of dolutegravir</u></p><p>All factors that decrease dolutegravir exposure should be avoided in the presence of integrase class resistance.</p><p>Dolutegravir is eliminated mainly through metabolism by UGT1A1. Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, Pgp, and BCRP; therefore medicinal products that induce those enzymes may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir (see Table 1). Co-administration of dolutegravir and other medicinal products that inhibit these enzymes may increase dolutegravir plasma concentration (see Table 1).</p><p>The absorption of dolutegravir is reduced by certain anti-acid agents (see Table 1).</p><p>&nbsp;</p><p><u>Effect of dolutegravir on the pharmacokinetics of other agents</u></p><p><em>In vivo</em>, dolutegravir did not have an effect on midazolam, a CYP3A4 probe.&nbsp; Based on <em>in vivo </em>and/or <em>in vitro</em> data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2).&nbsp;</p><p><em>In vitro</em>, dolutegravir inhibited the renal organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter (MATE) 1. <em>In vivo</em>, a 10-14% decrease of creatinine clearance (secretory fraction is dependent on OCT2 and MATE-1 transport) was observed in patients. &nbsp;<em>In vivo</em>, dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OCT2 and/or MATE-1 (e.g. fampridine [also known as dalfampridine], metformin) (see Table 1).</p><p><em>In vitro</em>, dolutegravir inhibited the renal uptake transporters, organic anion transporters (OAT1) and OAT3.&nbsp; Based on the lack of effect on the <em>in vivo</em> pharmacokinetics of the OAT substrate tenofovir, <em>in vivo</em> inhibition of OAT1 is unlikely. Inhibition of OAT3 has not been studied <em>in vivo</em>. Dolutegravir may increase plasma concentrations of medical products in which excretion is dependent upon OAT3.&nbsp;</p><p>Established and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed in Table 1.</p><p>&nbsp;</p><p>Interaction table</p><p>Interactions between dolutegravir and co-administered medicinal products are listed in Table 1 (increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;, no change as &ldquo;&harr;&rdquo;, area under the concentration versus time curve as &ldquo;AUC&rdquo;, maximum observed concentration as &ldquo;Cmax&rdquo;, concentration at end of dosing interval as &ldquo;C&tau;&rdquo;).</p><p>&nbsp;</p><p><strong>Table 1: Drug Interactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal products by therapeutic areas</strong></p></td><td style="vertical-align:top"><p><strong>Interaction </strong></p><p><strong>Geometric mean change (%) </strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning co‑administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HIV-1 Antiviral Agents</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Non-nucleoside Reverse Transcriptase Inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p>Etravirine without boosted protease inhibitors</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 71%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 52%<br />&nbsp;&nbsp; C&tau; &macr; 88%<br />&nbsp;</p><p>Etravirine &laquo;<br />(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>Etravirine without boosted protease inhibitors decreased plasma dolutegravir concentration. The recommended adult dose of dolutegravir is 50 mg twice daily when co-administered with etravirine without boosted protease inhibitors. Dolutegravir should not be used with etravirine without co-administration of atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir in INI-resistant patients (see further below in table).</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir/ritonavir + etravirine</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &shy; 11%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 7%<br />&nbsp;&nbsp; C&tau; &shy; 28%<br />LPV &laquo;<br />RTV &laquo;</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/ritonavir + etravirine</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 25%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 12%<br />&nbsp;&nbsp; C&tau; &macr; 36%<br />DRV &laquo;<br />RTV &laquo;</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 57%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 39%<br />&nbsp;&nbsp; C&tau; &macr; 75%<br />&nbsp;</p><p>Efavirenz &laquo; (historical controls)</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>The recommended adult dose of dolutegravir is 50&nbsp;mg twice daily when co-administered with efavirenz. In the presence of integrase class resistance alternative combinations that do not include efavirenz should be considered (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Nevirapine</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />(Not studied, a similar reduction in exposure as observed with efavirenz is expected, due to induction)</p></td><td style="vertical-align:top"><p>The recommended adult dose of dolutegravir is 50&nbsp;mg twice daily when co-administered with nevirapine. In the presence of integrase class resistance alternative combinations that do not include nevirapine should be considered (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Rilpivirine</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &shy; 12%</p><p>&nbsp;&nbsp; C<sub>max</sub> &shy; 13%</p><p>&nbsp;&nbsp; C&tau; &shy; 22%</p><p>Rilpivirine &laquo;</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Nucleoside Reverse Transcriptase Inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p>Tenofovir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &shy; 1%</p><p>&nbsp;&nbsp; C<sub>max</sub> &macr; 3%</p><p>&nbsp;&nbsp; C&tau;&nbsp; &macr; 8%</p><p>Tenofovir &laquo;</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Protease Inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir</p></td><td style="vertical-align:top"><p>Dolutegravir &shy;<br />&nbsp;&nbsp; AUC &shy; 91%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 50%<br />&nbsp;&nbsp; C&tau; &shy; 180%<br /><br />Atazanavir &laquo; (historical controls)</p><p>(inhibition of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p><p>&nbsp;</p><p>Tivicay should not be dosed higher than 50&nbsp;mg twice daily in combination with atazanavir (see section 5.2) due to lack of data.</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/ritonavir</p></td><td style="vertical-align:top"><p>Dolutegravir &shy;<br />&nbsp;&nbsp; AUC &shy; 62%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 34%<br />&nbsp;&nbsp; C&tau; &shy; 121%<br />&nbsp;</p><p>Atazanavir &laquo;<br />Ritonavir &laquo;</p><p>(inhibition of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p><p>&nbsp;</p><p>Tivicay should not be dosed higher than 50&nbsp;mg twice daily in combination with atazanavir (see section 5.2) due to lack of data.</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir/ritonavir (TPV+RTV)</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 59%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 47%<br />&nbsp;&nbsp; C&tau; &macr; 76%<br />(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>The recommended adult dose of dolutegravir is 50&nbsp;mg twice daily when co-administered with tipranavir/ritonavir.</p><p>In the presence of integrase class resistance this combination should be avoided (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir/ ritonavir (FPV+RTV)</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 35%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 24%<br />&nbsp;&nbsp; C&tau; &macr; 49%</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary in the absence of integrase class resistance. &nbsp;</p><p>In the presence of integrase class resistance alternative combinations that do not include fosamprenavir/ritonavir should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/ritonavir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 22%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 11%<br />&nbsp;&nbsp; C<sub>24</sub> &macr; 38%</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &macr; 4%</p><p>&nbsp;&nbsp; C<sub>max</sub> &laquo; 0%</p><p>&nbsp;&nbsp; C<sub>24</sub> &macr; 6%</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Other Antiviral agents</strong></p></td></tr><tr><td style="vertical-align:top"><p>Daclatasvir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &shy; 33%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 29%<br />&nbsp;&nbsp; Ct &shy; 45%</p><p>Daclatasvir &laquo;</p></td><td style="vertical-align:top"><p>Daclatasvir did not change dolutegravir plasma concentration to a clinically relevant extent.&nbsp; Dolutegravir did not change daclatasvir plasma concentration.&nbsp; No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Other agents</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Potassium channel blocker</em></p></td></tr><tr><td style="vertical-align:top"><p>Fampridine (also known as dalfampridine)</p></td><td style="vertical-align:top"><p>Fampridine &shy;</p></td><td style="vertical-align:top"><p>Co-administration of dolutegravir has the potential to cause seizures due to increased fampridine plasma concentration via inhibition of OCT2 transporter; co-administration has not been studied. Fampridine co-administration with dolutegravir is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Anticonvulsants</em></p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine<br />&nbsp;</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 49%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 33%<br />&nbsp;&nbsp; Ct &macr; 73%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>The recommended adult dose of dolutegravir is 50 mg twice daily when co-administered with carbamazepine. Alternatives to carbamazepine should be used where possible for INI resistant patients.</p></td></tr><tr><td style="vertical-align:top"><p>Oxcarbazepine<br />Phenytoin<br />Phenobarbital<br />&nbsp;</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;</p><p>(Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is expected)</p></td><td style="vertical-align:top"><p>The recommended adult dose of dolutegravir is 50 mg twice daily when co-administered with these metabolic inducers. Alternative combinations that do not include these metabolic inducers should be used where possible in INI-resistant patients.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Azole anti-fungal agents</em></p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole</p><p>Fluconazole</p><p>Itraconazole</p><p>Posaconazole</p><p>Voriconazole</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>(Not studied)</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.&nbsp; Based on data from other CYP3A4 inhibitors, a marked increase is not expected.&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Herbal products</em></p></td></tr><tr><td style="vertical-align:top"><p>St. John&rsquo;s wort</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;</p><p>(Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is expected)</p></td><td style="vertical-align:top"><p>The recommended adult dose of dolutegravir is 50 mg twice daily when co-administered with St. John&rsquo;s wort. Alternative combinations that do not include St. John&rsquo;s wort should be used where possible in INI-resistant patients.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Antacids and supplements</em></p></td></tr><tr><td style="vertical-align:top"><p>Magnesium/ aluminium-containing antacid</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 74%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 72%</p><p>(Complex binding to polyvalent ions)</p></td><td style="vertical-align:top"><p>Magnesium/ aluminium-containing antacid should be taken well separated in time from the administration of dolutegravir (minimum 2 hours after or 6 hours before).</p></td></tr><tr><td style="vertical-align:top"><p>Calcium supplements</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 39%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 37%<br />&nbsp;&nbsp; C<sub>24</sub> &macr; 39%</p><p>(Complex binding to polyvalent ions)</p></td><td rowspan="3" style="vertical-align:top"><p>Calcium supplements, iron supplements or multivitamins should be taken well separated in time from the administration of dolutegravir (minimum 2 hours after or 6 hours before).</p></td></tr><tr><td style="vertical-align:top"><p>Iron supplements</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 54%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 57%<br />&nbsp;&nbsp; C<sub>24</sub> &macr; 56%</p><p>(Complex binding to polyvalent ions)</p></td></tr><tr><td style="vertical-align:top"><p>Multivitamin</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;</p><p>&nbsp;&nbsp; AUC &macr; 33%</p><p>&nbsp;&nbsp; C<sub>max</sub> &macr; 35%</p><p>&nbsp;&nbsp; C<sub>24</sub> &macr; 32%</p><p>(Complex binding to polyvalent ions)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Corticosteroids</em></p></td></tr><tr><td style="vertical-align:top"><p>Prednisone</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &shy; 11%</p><p>&nbsp;&nbsp; C<sub>max</sub> &shy; 6%</p><p>&nbsp;&nbsp; C&tau; &shy; 17%</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Antidiabetics</em></p></td></tr><tr><td style="vertical-align:top"><p>Metformin</p></td><td style="vertical-align:top"><p>Metformin &shy;</p><p>When co-administered with dolutegravir 50mg once daily:</p><p>Metformin<br />&nbsp;&nbsp; AUC &shy; 79%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 66%</p><p>When co-administered with dolutegravir 50mg twice daily:</p><p>Metformin<br />&nbsp;&nbsp; AUC &shy; 145 %<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 111%</p></td><td style="vertical-align:top"><p>&nbsp;A dose adjustment of metformin should be considered when starting and stopping coadministration of dolutegravir with metformin, to maintain glycaemic control. In patients with moderate renal impairment a dose adjustment of metformin should be considered when coadministered with dolutegravir, because of the increased risk for lactic acidosis in patients with moderate renal impairment due to increased metformin concentration (section 4.4).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Antimycobacterials</em></p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 54%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 43%<br />&nbsp;&nbsp; C&tau; &macr;72%</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>The recommended adult dose of dolutegravir is 50&nbsp;mg twice daily when co-administered with rifampicin in the absence of integrase class resistance.&nbsp;</p><p>In the presence of integrase class resistance this combination should be avoided (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &macr; 5%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 16%<br />&nbsp;&nbsp; C&tau; &macr; 30%</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Oral contraceptives</em></p></td></tr><tr><td style="vertical-align:top"><p>Ethinyl estradiol (EE) and Norelgestromin (NGMN)</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>EE &laquo;<br />&nbsp;&nbsp; AUC &shy; 3%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 1%<br />&nbsp;</p><p>NGMN &laquo;<br />&nbsp;&nbsp; AUC &macr; 2%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 11%</p></td><td style="vertical-align:top"><p>Dolutegravir had no pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone. No dose adjustment of oral contraceptives is necessary when co-administered with dolutegravir.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Analgesics</em></p></td></tr><tr><td style="vertical-align:top"><p>Methadone</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>Methadone &laquo;<br />&nbsp;&nbsp; AUC &macr; 2%<br />&nbsp;&nbsp; C<sub>max</sub> &laquo; 0%<br />&nbsp;&nbsp; Ct &macr; 1%</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary of either agent.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential </u></p><p>Women of childbearing potential (WOCBP) should be counselled about the potential risk of neural tube defects with dolutegravir (see below), including consideration of effective contraceptive measures.</p><p>If a woman plans pregnancy, the benefits and the risks of continuing treatment with dolutegravir should be discussed with the patient.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Human experience from a birth outcome surveillance study in Botswana shows a small increase of neural tube defects; 7 cases in 3,591 deliveries (0.19%; 95% CI 0.09%, 0.40%) to mothers taking dolutegravir-containing regimens at the time of conception compared to 21 cases in 19,361 deliveries (0.11%: 95% CI 0.07%, 0.17%) to women exposed to non-dolutegravir regimens at the time of conception.</p><p>The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births (0.05-0.1%).&nbsp; &nbsp;Most neural tube defects occur within the first 4 weeks of embryonic development after conception (approximately 6 weeks after the last menstrual period). &nbsp;If a pregnancy is confirmed in the first trimester while on dolutegravir, the benefits and risks of continuing dolutegravir versus switching to another antiretroviral regimen should be discussed with the patient taking the gestational age and the critical time period of neural tube defect development into account.</p><p>Data analysed from the Antiretroviral Pregnancy Registry do not indicate an increased risk of major birth defects in over 600 women exposed to dolutegravir during pregnancy but are currently insufficient to address the risk of neural tube defects.</p><p>In animal reproductive toxicity studies, no adverse development outcomes, including neural tube defects, were identified (see section 5.3).</p><p>More than 1000 outcomes from exposure during second and third trimester of pregnancy indicate no evidence of increased risk of foetal/neonatal toxicity. Dolutegravir may be used during the second and third trimester of pregnancy when the expected benefit justifies the potential risk to the foetus.</p><p>Dolutegravir crosses the placenta in humans. In pregnant women living with HIV, the median foetal umbilical cord concentration of dolutegravir was approximately 1.3-fold greater compared with the maternal peripheral plasma concentration.</p><p>There is insufficient information on the effects of dolutegravir on neonates.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Dolutegravir is excreted in human milk in small amounts (a median dolutegravir breast milk to maternal plasma ratio of 0.033 has been shown). There is insufficient information on the effects of dolutegravir in neonates/infants.</p><p>It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission of HIV.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on the effects of dolutegravir on human male or female fertility. Animal studies indicate no effects of dolutegravir on male or female fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be informed that dizziness has been reported during treatment with dolutegravir. The clinical status of the patient and the adverse reaction profile of dolutegravir should be borne in mind when considering the patient&#39;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most severe adverse reaction, seen in an individual patient, was a hypersensitivity reaction that included rash and severe liver effects (see section 4.4).&nbsp; The most commonly seen treatment emergent adverse reactions were nausea (13%), diarrhoea (18%) and headache (13%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse reactions considered at least possibly related to dolutegravir are listed by body system, organ class and absolute frequency. Frequencies are defined as very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><p>&nbsp;</p><p><strong>Table 2 Adverse Reactions</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:586px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypersensitivity (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Immune Reconstitution Syndrome (see section 4.4)**</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abnormal dreams</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anxiety</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Panic attack</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Suicidal ideation*, suicide attempt*</p><p>*particularly in patients with a pre-existing history of depression or psychiatric illness.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Completed suicide*</p><p>*particularly in patients with a pre-existing history of depression or psychiatric illness.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Flatulence</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Upper abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal discomfort</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) elevations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Acute hepatic failure, increased bilirubin***</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Creatine phosphokinase (CPK) elevations, weight increased</p></td></tr></tbody></table><p>&nbsp;</p><p>**see below under Description of selected adverse reactions.</p><p>***in combination with increased transaminases</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Changes in laboratory biochemistries</em></p><p>Increases in serum creatinine occurred within the first week of treatment with dolutegravir and remained stable through 48 weeks. A mean change from baseline of 9.96&nbsp;mmol/L was observed after 48 weeks of treatment. Creatinine increases were comparable by various background regimens. These changes are not considered to be clinically relevant since they do not reflect a change in glomerular filtration rate.</p><p>&nbsp;</p><p><em>Co-infection with Hepatitis B or C</em></p><p>In Phase III studies patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN). Overall, the safety profile in patients co-infected with hepatitis B and/or C was similar to that observed in patients without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C co-infection for all treatment groups. Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some subjects with hepatitis B and/or C co-infection at the start of dolutegravir therapy, particularly in those whose anti-hepatitis B therapy was withdrawn (see section 4.4).</p><p>&nbsp;</p><p><em>Immune reactivation syndrome</em></p><p>In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.&nbsp; Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).</p><p>&nbsp;</p><p><em>Metabolic parameters</em></p><p>Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-The National Pharmacovigilance Centre (NPC)</strong></p><ul><li>Reporting Hotline: 19999</li><li>E-mail : npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: saudi.safety@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com&nbsp;</li><li>Website: https://gskpro.com/en-sa/ &nbsp;&nbsp;</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is currently limited experience with overdosage in dolutegravir.</p><p>Limited experience of single higher doses (up to 250 mg in healthy subjects) revealed no specific symptoms or signs, apart from those listed as adverse reactions.&nbsp;</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.&nbsp; There is no specific treatment for an overdose of dolutegravir. If overdose occurs, the patient should be treated supportively with appropriate monitoring, as necessary. As dolutegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, other antivirals, ATC code: J05AJ03<!--[if supportFields]><span style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e9942cc6-1949-44cf-bffa-a2b009e0a619 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p><u>Mechanism of action</u></p><p>Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.</p><p><u>Pharmacodynamic effects</u></p><p><em>Antiviral activity in cell culture </em></p><p>The IC50 for dolutegravir in various lab strains using PBMC was 0.5 nM, and when using MT-4 cells it ranged from 0.7-2 nM. Similar IC50s were seen for clinical isolates without any major difference between subtypes; in a panel of 24 HIV-1 isolates of clades A, B, C, D, E, F and G and group O the mean IC50 value was 0.2 nM (range 0.02-2.14). The mean IC50 for 3 HIV-2 isolates was 0.18 nM (range 0.09-0.61).</p><p><em>Antiviral activity in combination with other antiviral agents</em></p><p>No antagonistic effects <em>in vitro</em> were seen with dolutegravir and other antiretrovirals tested: stavudine, abacavir, efavirenz, nevirapine, lopinavir, amprenavir, enfuvirtide, maraviroc and raltegravir.&nbsp; In addition, no antagonistic effects were seen for dolutegravir and adefovir, and ribavirin had no apparent effect on dolutegravir activity.</p><p><em>Effect of human serum </em></p><p>In 100% human serum, the mean protein fold shift was 75-fold, resulting in protein adjusted IC90 of 0.064 &micro;g/mL<em>. </em></p><p><u>Resistance</u></p><p><em>Resistance in vitro</em></p><p>Serial passage is used to study resistance evolution <em>in vitro</em>. When using the lab-strain HIV-1 IIIB during passage over 112 days, mutations selected appeared slowly, with substitutions at positions S153Y and F, resulting in a maximal fold change in susceptibility of 4 (range 2-4). These mutations were not selected in patients treated with dolutegravir in the clinical studies.&nbsp; Using strain NL432, mutations E92Q (FC 3) and G193E (also FC 3) were selected. The E92Q mutation has been selected in patients with pre-existing raltegravir resistance who were then treated with dolutegravir (listed as a secondary mutation for dolutegravir).</p><p>In further selection experiments using clinical isolates of subtype B, mutation R263K was seen in all five isolates (after 20 weeks and onwards). In subtype C (n=2) and A/G (n=2) isolates the integrase substitution R263K was selected in one isolate, and G118R in two isolates. &nbsp;R263K was reported from two ART experienced, INI naive individual patients with subtypes B and C in the clinical program, but without effects on dolutegravir susceptibility <em>in vitro</em>. G118R lowers the susceptibility to dolutegravir in site directed mutants (FC 10), but was not detected in patients receiving dolutegravir in the Phase III program.&nbsp;</p><p>Primary mutations for raltegravir/elvitegravir (Q148H/R/K, N155H, Y143R/H/C, E92Q and T66I) do not affect the <em>in vitro</em> susceptibility of dolutegravir as single mutations. When mutations listed as secondary integrase inhibitor associated mutations (for raltegravir/elvitegravir) are added to these primary mutations in experiments with site directed mutants, dolutegravir susceptibility is still unchanged (FC &lt;2 vs wild type virus), except in the case of Q148-mutations, where a FC of 5-10 or higher is seen with combinations of certain secondary mutations. The effect by the Q148-mutations (H/R/K) was also verified in passage experiments with site directed mutants.&nbsp; In serial passage with strain NL432, starting with site directed mutants harbouring N155H or E92Q, no further selection of resistance was seen (FC unchanged around 1). In contrast, starting with mutants harbouring mutation Q148H (FC 1), a variety of secondary mutations were seen with a consequent increase of FC to values &gt;10.</p><p>A clinically relevant phenotypic cut-off value (FC vs wild type virus) has not been determined; genotypic resistance was a better predictor for outcome.</p><p>Seven hundred and five raltegravir resistant isolates from raltegravir experienced patients were analyzed for susceptibility to dolutegravir.&nbsp; Dolutegravir has a less than or equal to 10 FC against 94% of the 705 clinical isolates.</p><p><em>Resistance in vivo</em></p><p>In previously untreated patients receiving dolutegravir + 2 NRTIs in Phase IIb and Phase III, no development of resistance to the integrase class, or to the NRTI class was seen (n=1118 follow-up of 48-96 weeks). In previously untreated patients receiving dolutegravir + lamivudine in the GEMINI studies through week 144 (n=716), no development of resistance to the integrase class, or to the NRTI class was seen.</p><p>In patients with prior failed therapies, but na&iuml;ve to the integrase class (SAILING study), integrase inhibitor substitutions were observed in 4/354 patients (follow-up 48 weeks) treated with dolutegravir, which was given in combination with an investigator selected background regimen (BR). Of these four, two subjects had a unique R263K integrase substitution, with a maximum FC of 1.93, one subject had a polymorphic V151V/I integrase substitution, with maximum FC of 0.92, and one subject had pre-existing integrase mutations and is assumed to have been integrase experienced or infected with integrase resistant virus by transmission. The R263K mutation was also selected <em>in vitro</em> (see above).</p><p>In the presence of integrase class-resistance (VIKING-3 study) the following mutations were selected in 32 patients with protocol defined virological failure (PDVF) through Week 24 and with paired genotypes (all treated with dolutegravir 50&nbsp;mg twice daily + optimized background agents):&nbsp; L74L/M (n=1), E92Q (n=2), T97A (n=9), E138K/A/T (n=8), G140S (n=2), Y143H (n=1), S147G (n=1), Q148H/K/R (n=4), and N155H (n=1) and E157E/Q (n=1).&nbsp; Treatment emergent integrase resistance typically appeared in patients with a history of the Q148-mutation (baseline or historic). Five further subjects experienced PDVF between weeks 24 and 48, and 2 of these 5 had treatment emergent mutations.&nbsp; Treatment-emergent mutations or mixtures of mutations observed were L74I (n=1), N155H (n=2).</p><p>The VIKING-4 study examined dolutegravir (plus optimized background therapy) in subjects with primary genotypic resistance to INIs at Screening in 30 subjects.&nbsp; Treatment-emergent mutations observed were consistent with those observed in the VIKING-3 study.</p><p><u>Effects on electrocardiogram</u></p><p>No relevant effects were seen on the QTc interval, with doses exceeding the clinical dose by approximately three fold.</p><p><u>Clinical efficacy and safety</u><strong> </strong></p><p><em><u>Previously untreated patients </u></em></p><p>The efficacy of dolutegravir in HIV-infected, therapy na&iuml;ve subjects is based on the analyses of 96-week data from two randomized, international, double-blind, active-controlled trials, SPRING-2 (ING113086) and SINGLE (ING114467). This is supported by 96 week data from an open-label, randomized and active-controlled study FLAMINGO (ING114915) and additional data from the open-label phase of SINGLE to 144 weeks. The efficacy of dolutegravir in combination with lamivudine in adults is supported by 144-week data from two identical 148-week, randomised, multicentre, double-blind, non-inferiority studies GEMINI-1 (204861) and GEMINI-2 (205543).</p><p>In SPRING-2, 822 adults were randomized and received at least one dose of either dolutegravir 50&nbsp;mg once daily or raltegravir (RAL) 400&nbsp;mg twice daily, both administered with either ABC/3TC or TDF/FTC.&nbsp; At baseline, median patient age was 36 years, 14% were female, 15% non-white, 11% had hepatitis B and/or C co-infection and 2% were CDC Class C, these characteristics were similar between treatment groups.</p><p>In SINGLE, 833 subjects were randomized and received at least one dose of either dolutegravir 50&nbsp;mg once daily with fixed-dose abacavir-lamivudine (Dolutegravir + ABC/3TC) or fixed-dose efavirenz-tenofovir-emtricitabine (EFV/TDF/FTC). At baseline, median patient age was 35 years, 16% were female, 32% non-white, 7% had hepatitis C co-infection and 4% were CDC Class C, these characteristics were similar between treatment groups.</p><p>The primary endpoint and other week 48 outcomes (including outcomes by key baseline covariates)<strong> </strong>for SPRING-2 and SINGLE are shown in Table 3.</p><p><strong>Table </strong><strong>3</strong><strong> Response in</strong> <strong>SPRING-2 and SINGLE at 48 Weeks (Snapshot algorithm, &lt;50 copies/mL)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>SPRING-2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>SINGLE</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dolutegravir 50&nbsp;mg Once Daily + 2 NRTI</strong></p><p><strong>N=411</strong></p></td><td style="vertical-align:top"><p><strong>RAL 400&nbsp;mg Twice Daily + 2 NRTI</strong></p><p><strong>N=411</strong></p></td><td style="vertical-align:top"><p><strong>Dolutegravir 50&nbsp;mg + ABC/3TC Once Daily</strong></p><p><strong>N=414</strong></p></td><td style="vertical-align:top"><p><strong>EFV/TDF/FTC Once Daily</strong></p><p><strong>N=419</strong></p></td></tr><tr><td><p><strong>HIV-1 RNA &lt;50 copies/mL</strong></p></td><td style="vertical-align:top"><p>88%</p></td><td style="vertical-align:top"><p>85%</p></td><td style="vertical-align:top"><p>88%</p></td><td style="vertical-align:top"><p>81%</p></td></tr><tr><td><p>&nbsp; <strong>Treatment Difference</strong>*</p></td><td colspan="2" style="vertical-align:top"><p>2.5% (95% CI: -2.2%, 7.1%)</p></td><td colspan="2" style="vertical-align:top"><p>7.4% (95% CI: 2.5%, 12.3%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Virologic non-response&dagger; </strong></p></td><td><p>5%</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>HIV-1 RNA &lt;50 copies/mL by baseline covariates</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline Viral Load (cps/mL)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &pound;100,000</p></td><td><p>267 / 297 (90%)</p></td><td><p>264 / 295 (89%)</p></td><td><p>253 / 280 (90%)</p></td><td><p>238 / 288 (83%)</p></td></tr><tr><td><p>&nbsp; &gt;100,000</p></td><td><p>94 / 114 (82%)</p></td><td><p>87 / 116 (75%)</p></td><td><p>111 / 134 (83%)</p></td><td><p>100 / 131 (76%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline CD4+ (cells/ mm<sup>3</sup>)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &lt;200</p></td><td style="vertical-align:top"><p>43 / 55 (78%)</p></td><td style="vertical-align:top"><p>34 / 50 (68%)</p></td><td style="vertical-align:top"><p>45 / 57 (79%)</p></td><td style="vertical-align:top"><p>48 / 62 (77%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; 200 to &lt;350</p></td><td style="vertical-align:top"><p>128 / 144 (89%)</p></td><td style="vertical-align:top"><p>118 / 139 (85%)</p></td><td style="vertical-align:top"><p>143 / 163 (88%)</p></td><td style="vertical-align:top"><p>126 / 159 (79%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &sup3;350</p></td><td style="vertical-align:top"><p>190 / 212 (90%)</p></td><td style="vertical-align:top"><p>199 / 222 (90%)</p></td><td style="vertical-align:top"><p>176 / 194 (91%)</p></td><td style="vertical-align:top"><p>164 / 198 (83%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>NRTI backbone</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp; </strong>ABC/3TC</p></td><td style="vertical-align:top"><p>145 / 169 (86%)</p></td><td style="vertical-align:top"><p>142 / 164 (87%)</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; TDF/FTC</p></td><td style="vertical-align:top"><p>216 / 242 (89%)</p></td><td style="vertical-align:top"><p>209 / 247 (85%)</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gender</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Male</p></td><td><p>308 / 348 (89%)</p></td><td><p>305 / 355 (86%)</p></td><td><p>307 / 347 (88%)</p></td><td><p>291 / 356 (82%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Female</p></td><td><p>53 / 63 (84%)</p></td><td><p>46 / 56 (82%)</p></td><td><p>57 / 67 (85%)</p></td><td><p>47 / 63 (75%)</p></td></tr><tr><td><p><strong>Race </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; White</p></td><td><p>306 / 346 (88%)</p></td><td><p>301 / 352 (86%)</p></td><td><p>255 / 284 (90%)</p></td><td><p>238 /285 (84%)</p></td></tr><tr><td><p>&nbsp; African-America/African Heritage/Other</p></td><td><p>55 / 65 (85%)</p></td><td><p>50 / 59 (85%)</p></td><td><p>109 / 130 (84%)</p></td><td><p>99 / 133 (74%)</p></td></tr><tr><td><p><strong>Age (years)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; &lt;50</p></td><td><p>324/370 (88%)</p></td><td><p>312/365 (85%)</p></td><td><p>319/361 (88%)</p></td><td><p>302/375 (81%)</p></td></tr><tr><td><p>&nbsp; &sup3;50</p></td><td><p>37/41 (90%)</p></td><td><p>39/46 (85%)</p></td><td><p>45/53 (85%)</p></td><td><p>36/44 (82%)</p></td></tr><tr><td><p>Median CD4 change from baseline</p></td><td><p>230</p></td><td><p>230</p></td><td><p>246&Dagger;</p></td><td><p>187&Dagger;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>* Adjusted for baseline stratification factors.</p><p>&dagger; Includes subjects who changed BR to new class or changed BR not permitted per protocol or due to lack of efficacy prior to Week 48 (for SPRING-2 only), subjects who discontinued prior to Week 48 for lack or loss of efficacy and subjects who are &sup3;50 copies in the 48 week window.</p><p>&Dagger; Adjusted mean treatment difference was statistically significant (p&lt;0.001)</p></td></tr></tbody></table><p>At week 48, dolutegravir was non-inferior to raltegravir in the SPRING-2 study, and in the SINGLE study dolutegravir + ABC/3TC was superior to efavirenz/TDF/FTC (p=0.003), table 3 above. In SINGLE, the median time to viral suppression was shorter in the dolutegravir treated patients (28 vs 84 days, (p&lt;0.0001, analysis pre-specified and adjusted for multiplicity).</p><p>At week 96, results were consistent with those seen at week 48.&nbsp; In SPRING-2, dolutegravir was still non-inferior to raltegravir (viral suppression in 81% vs 76% of patients), and with a median change in CD4 count of 276 vs 264 cells/mm<sup>3</sup>, respectively. &nbsp;In SINGLE, dolutegravir + ABC/3TC was still superior to EFV/TDF/FTC (viral suppression in 80% vs 72%, treatment difference 8.0% (2.3, 13.8), p=0.006, and with an adjusted mean change in CD4 count of 325 vs 281 cells/ mm<sup>3</sup>, respectively.&nbsp; At 144 weeks in the open-label phase of SINGLE, virologic suppression was maintained, the dolutegravir + ABC/3TC arm (71%) was superior to the EFV/TDF/FTC arm (63%), treatment difference was 8.3% (2.0, 14.6).</p><p>In FLAMINGO (ING114915), an open-label, randomised and active-controlled study, 484 HIV-1 infected antiretroviral na&iuml;ve adults received one dose of either dolutegravir 50&nbsp;mg once daily (n=242) or darunavir/ritonavir (DRV/r) 800&nbsp;mg/100&nbsp;mg once daily (n=242), both administered with either ABC/3TC or TDF/FTC.&nbsp; At baseline, median patient age was 34 years, 15% were female, 28% non-white, 10% had hepatitis B and/or C co-infection, and 3% were CDC Class C; these characteristics were similar between treatment groups.&nbsp; Virologic suppression (HIV-1 RNA &lt;50 copies/mL) in the dolutegravir group (90%) was superior to the DRV/r group (83%) at 48 weeks. The adjusted difference in proportion and 95% CI were 7.1% (0.9, 13.2), p=0.025. At 96 weeks, virologic suppression in the dolutegravir group (80%) was superior to the DRV/r group (68%), (adjusted treatment difference [Dolutegravir-(DRV+RTV)]: 12.4%; 95% CI: [4.7, 20.2].</p><p>In GEMINI-1 (204861) and GEMINI-2 (205543), identical 148-week, randomised, double-blind studies, 1433 adult HIV-1 infected antiretroviral na&iuml;ve subjects were randomised to either a two-drug regimen of dolutegravir 50 mg plus lamivudine 300 mg once daily, or to a three-drug regimen of dolutegravir 50 mg once daily with fixed dose TDF/FTC. Subjects were enrolled with a screening plasma HIV-1 RNA of 1000 c/mL to &le;500,000 c/mL. At baseline, in the pooled analysis, median patient age was 33 years, 15% were female, 31% non-white, 6% had hepatitis C co-infection and 9% were CDC Stage 3. Approximately one third of the patients were infected with an HIV non-B subtype; these characteristics were similar between treatment groups. Virologic suppression (HIV-1 RNA &lt;50 copies/mL) in the dolutegravir plus lamivudine group was non-inferior to the dolutegravir plus TDF/FTC group at 48 weeks, as shown in Table 4. The results of the pooled analysis were in line with those of the individual studies, for which the primary endpoint (difference in proportion &lt;50 copies/mL plasma HIV-1 RNA at week 48 based on the Snapshot algorithm) was met. The adjusted difference was -2.6% (95% CI: -6.7; 1.5) for GEMINI-1 and -0.7% (95% CI: -4.3; 2.9) for GEMINI-2 with a prespecified non-inferiority margin of 10%.</p><p><strong>Table 4 Response (&lt;50 cps/ml, snapshot) in GEMINI 1 + 2, pooled data at Week 48. </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dolutegravir + 3TC</strong></p><p><strong>(N=716)<br />n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Dolutegravir + TDF/FTC</strong></p><p><strong>(N=717)<br />n/N (%)</strong></p></td></tr><tr><td><p>All patients</p></td><td><p>655/716 (91)</p></td><td><p>669/717 (93)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>adjusted diff -1.7% (CI95-4.4, 1.1) <sup>a</sup></p></td></tr><tr><td colspan="3"><p>By BL HIV-1 RNA</p></td></tr><tr><td><p>&le;100,000 cps/mL</p></td><td><p>526/576 (91)</p></td><td><p>531/564 (94)</p></td></tr><tr><td><p>&gt;100,000 cps/mL</p></td><td><p>129/140 (92)</p></td><td><p>138/153 (92)</p></td></tr><tr><td colspan="3"><p>By CD4+</p></td></tr><tr><td><p>&le;200 c/ mm3</p></td><td><p>50/63 (79)</p></td><td><p>51/55 (93)</p></td></tr><tr><td><p>&gt;200 c/ mm3</p></td><td><p>605/653 (93)</p></td><td><p>618/662 (93)</p></td></tr><tr><td colspan="3"><p>By HIV-1 subtype</p></td></tr><tr><td><p>B</p></td><td><p>424/467 (91)</p></td><td><p>452/488 (93)</p></td></tr><tr><td><p>Non-B</p></td><td><p>231/249 (93)</p></td><td><p>217/229 (95)</p></td></tr><tr><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Rebound up to week 48 <sup>b</sup></p></td><td><p>6 (&lt;1)</p></td><td><p>4 (&lt;1)</p></td></tr><tr><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Mean change in CD4 count from baseline at Week 48, c/ mm3</p></td><td><p>224</p></td><td><p>217</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a </sup>adjusted for BL stratification factors: Plasma HIV-1 RNA (&le;100,000 cps/mL vs. &gt;100,000 cps/mL) and CD4+ cell count (&le;200 cells/mm3 vs. &gt;200 cells/mm3).</p><p><sup>b</sup> Confirmed plasma HIV-1 RNA levels to &ge;200 cps/mL after prior confirmed suppression to &lt;200 cps/mL.</p></td></tr></tbody></table><p>&nbsp;At 96 weeks and at 144 weeks in the GEMINI studies, the lower bound of the 95% confidence interval for the adjusted treatment difference of proportion of subjects with HIV-1 RNA &lt;50 copies/mL (snapshot) was greater than the non-inferiority margin of -10%, for the individual studies as well as pooled analysis, see Table 5.</p><p><strong>Table 5</strong> <strong>Virologic Outcomes (snapshot algorithm) in GEMINI 1 + 2, pooled data at Weeks&nbsp;96 and 144</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>GEMINI-1 and GEMINI-2 Pooled Data</strong>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>DTG + 3TC</strong></p><p><strong>N=716</strong></p></td><td style="vertical-align:top"><p><strong>DTG + TDF/FTC</strong></p><p><strong>N=717</strong></p></td><td style="vertical-align:top"><p><strong>DTG + 3TC</strong></p><p><strong>N=716</strong></p></td><td style="vertical-align:top"><p><strong>DTG + TDF/FTC</strong></p><p><strong>N=717</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p>Week 96</p></td><td colspan="2" style="vertical-align:top"><p>Week 144</p></td></tr><tr><td><p><strong>HIV-1 RNA &lt;50&nbsp;copies/mL</strong></p></td><td style="vertical-align:top"><p>86%</p></td><td style="vertical-align:top"><p>90%</p></td><td style="vertical-align:top"><p>82%</p></td><td style="vertical-align:top"><p>84%</p></td></tr><tr><td><p><strong>&nbsp;Treatment Difference</strong><sup>&dagger; </sup><br />(95%<sup> </sup>confidence intervals)</p></td><td colspan="2"><p>-3.4% (-6.7, 0.0)</p></td><td colspan="2"><p>-1.8% (-5.8; 2.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Virologic non response</strong></p></td><td><p>3%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p><u>Reasons</u></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Data in window, &ge;50&nbsp;cps/mL</p></td><td><p>&lt;1%</p></td><td><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr><tr><td><p>Discontinued, lack of efficacy</p></td><td><p>1%</p></td><td><p>&lt;1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued, other reasons, &ge;50&nbsp;cps/mL</p></td><td><p>&lt;1%</p></td><td><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Change in ART</p></td><td><p>&lt;1%</p></td><td><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p><strong>No virologic data at Week 96/Week 144 window</strong></p><p><u>Reasons</u></p><p>Discontinued study due to AE or death</p><p>Discontinued study for other reasons</p><p>Loss to follow-up</p><p>Withdrew consent</p><p>Protocol deviations</p><p>Physicians decision</p><p>Missing data in window, on study</p></td><td style="vertical-align:top"><p>11%</p><p>&nbsp;</p><p>&nbsp;</p><p>3%</p><p>8%</p><p>3%</p><p>3%</p><p>1%</p><p>1%</p><p>0%</p></td><td style="vertical-align:top"><p>9%</p><p>&nbsp;</p><p>&nbsp;</p><p>3%</p><p>5%</p><p>1%</p><p>2%</p><p>1%</p><p>&lt;1%</p><p>&lt;1%</p></td><td style="vertical-align:top"><p>15%</p><p>&nbsp;</p><p>&nbsp;</p><p>4%</p><p>11%</p><p>3%</p><p>4%</p><p>2%</p><p>2%</p><p>&lt;1%</p></td><td style="vertical-align:top"><p>14%</p><p>&nbsp;</p><p>&nbsp;</p><p>4%</p><p>9%</p><p>3%</p><p>3%</p><p>1%</p><p>1%</p><p>&lt;1%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>DTG=Dolutegravir</p><p>*<em> </em>The results of the pooled analysis are in line with those of the individual studies.</p><p>&dagger; Based on CMH-stratified analysis adjusting for the following baseline stratification factors: Plasma HIV-1 RNA (&le;100,000&nbsp;c/mL vs. &gt;100,000&nbsp;c/mL) and CD4+ cell count (&le;200&nbsp;cells/mm<sup>3</sup>&nbsp;vs.&nbsp;&gt;200&nbsp;cells/mm<sup>3</sup>). Pooled analysis also stratified by study. Assessed using a non‑inferiority margin of 10%.</p><p>N = Number of subjects in each treatment group</p></td></tr></tbody></table><p>The mean increase in CD4+ T-cell counts through week 144 was 302 cells/mm<sup>3</sup> in the dolutegravir plus lamivudine arm and 300 cells/mm<sup>3</sup> in the dolutegravir plus tenofovir/emtricitabine arm.<!--[if supportFields]><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9121d242-7efd-4151-b3cf-509864ab8930 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p><em>Treatment emergent resistance in previously untreated patients failing therapy</em></p><p>Through 96 weeks in SPRING-2 and FLAMINGO and 144 weeks in SINGLE, no cases of treatment emergent primary resistance to the integrase- or NRTI-class were seen in the dolutegravir-containing arms. For the comparator arms, the same lack of treatment emergent resistance was also the case for patients treated with darunavir/r in FLAMINGO. In SPRING-2, four patients in the RAL-arm failed with major NRTI mutations and one with raltegravir resistance; in SINGLE, six patients in the EFV/TDF/FTC-arm failed with mutations associated with NNRTI resistance, and one developed a major NRTI mutation. Through 144 weeks in the GEMINI-1 and GEMINI-2 studies, no cases of emergent resistance to the integrase- or NRTI-class were seen in either the Dolutegravir+3TC or comparator Dolutegravir+TDF/FTC arms.</p><p><em><u>Patients with prior treatment failure, but not exposed to the integrase class </u></em></p><p>In the international multicentre, double-blind SAILING study (ING111762), 719 HIV-1 infected, antiretroviral therapy (ART)-experienced adults were randomized and received either dolutegravir 50&nbsp;mg once daily or raltegravir 400&nbsp;mg twice daily with investigator selected background regimen consisting of up to 2 agents (including at least one fully active agent).&nbsp; At baseline, median patient age was 43 years, 32% were female, 50% non-white, 16% had hepatitis B and/or C co-infection, and 46% were CDC Class C.&nbsp; All patients had at least two class ART resistance, and 49% of subjects had at least 3-class ART resistance at baseline.</p><p>Week 48 outcomes (including outcomes by key baseline covariates) for SAILING are shown in Table 5.</p><p><strong>Table </strong><strong>6 Response in SAILING at 48 Weeks (Snapshot algorithm, &lt;50 copies/mL)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dolutegravir 50&nbsp;mg Once Daily + BR</strong></p><p><strong>N=354&sect;</strong></p></td><td style="vertical-align:top"><p><strong>RAL 400&nbsp;mg Twice Daily + BR</strong></p><p><strong>N=361&sect;</strong></p></td></tr><tr><td><p><strong>HIV-1 RNA &lt;50 copies/mL</strong></p></td><td style="vertical-align:top"><p>71%</p></td><td style="vertical-align:top"><p>64%</p></td></tr><tr><td><p>&nbsp; Adjusted treatment difference&Dagger;</p></td><td colspan="2" style="vertical-align:top"><p>7.4% (95% CI: 0.7%, 14.2%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Virologic non-response</strong></p></td><td><p>20%</p></td><td style="vertical-align:top"><p>28%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HIV-1 RNA &lt;50 copies/mL by baseline covariates</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline Viral Load (copies/mL)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &pound;50,000 copies/mL</p></td><td><p>186 / 249 (75%)</p></td><td><p>180 / 254 (71%)</p></td></tr><tr><td><p>&nbsp; &gt;50,000 copies/mL</p></td><td><p>65 / 105 (62%)</p></td><td><p>50 / 107 (47%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline CD4+ (cells/ mm<sup>3</sup>)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &lt;50</p></td><td><p>33 / 62 (53%)</p></td><td><p>30 / 59 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; 50 to &lt;200</p></td><td><p>77 / 111 (69%)</p></td><td><p>76 / 125 (61%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; 200 to &lt;350</p></td><td><p>64 / 82 (78%)</p></td><td><p>53 / 79 (67%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &sup3;350</p></td><td><p>77 / 99 (78%)</p></td><td><p>71 / 98 (72%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Background Regimen</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Genotypic Susceptibility Score* &lt;2</p></td><td><p>155 / 216 (72%)</p></td><td><p>129 / 192 (67%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Genotypic Susceptibility Score* =2</p></td><td><p>96 / 138 (70%)</p></td><td><p>101 / 169 (60%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp; Use of DRV in background regimen</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; No DRV use</p></td><td><p>143 / 214 (67%)</p></td><td><p>126 / 209 (60%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; DRV use with primary PI mutations</p></td><td><p>58 / 68 (85%)</p></td><td><p>50 / 75 (67%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; DRV use without primary PI mutations</p></td><td><p>50 / 72 (69%)</p></td><td><p>54 / 77 (70%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gender</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Male</p></td><td><p>172 / 247 (70%)</p></td><td><p>156 / 238 (66%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Female</p></td><td><p>79 / 107 (74%)</p></td><td><p>74 / 123 (60%)</p></td></tr><tr><td><p><strong>Race </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; White</p></td><td><p>133 / 178 (75%)</p></td><td><p>125 / 175 (71%)</p></td></tr><tr><td><p>&nbsp; African-America/African Heritage/Other</p></td><td><p>118 / 175 (67%)</p></td><td><p>105 / 185 (57%)</p></td></tr><tr><td><p><strong>Age (years)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; &lt;50</p></td><td><p>196 / 269 (73%)</p></td><td><p>172 / 277 (62%)</p></td></tr><tr><td><p>&nbsp; &sup3;50</p></td><td><p>55 / 85 (65%)</p></td><td><p>58 / 84 (69%)</p></td></tr><tr><td><p><strong>HIV sub type</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; Clade B</p></td><td><p>173 / 241 (72%)</p></td><td><p>159 / 246 (65%)</p></td></tr><tr><td><p>&nbsp; Clade C</p></td><td><p>34 / 55 (62%)</p></td><td><p>29 / 48 (60%)</p></td></tr><tr><td><p>&nbsp; Other&dagger;</p></td><td><p>43 / 57 (75%)</p></td><td><p>42 / 67 (63%)</p></td></tr><tr><td><p>Mean increase in CD4+ T cell (cells/mm<sup>3</sup>)</p></td><td><p>162</p></td><td><p>153</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&Dagger; Adjusted for baseline stratification factors.</p><p>&sect; 4 subjects were excluded from the efficacy analysis due to data integrity at one study site</p><p>*The Genotypic Susceptibility Score (GSS) was defined as the total number of ARTs in BR to which a subject&rsquo;s viral isolate showed susceptibility at baseline based upon genotypic resistance tests.&nbsp;</p><p>&dagger;Other clades included: Complex (43), F1 (32), A1 (18), BF (14), all others &lt;10.</p><p>&nbsp;</p></td></tr></tbody></table><p>In the SAILING study, virologic suppression (HIV-1 RNA &lt;50 copies/mL) in the Tivicay arm (71%) was statistically superior to the raltegravir arm (64%), at Week 48 (p=0.03).</p><p>Statistically fewer subjects failed therapy with treatment-emergent integrase resistance on Tivicay (4/354, 1%) than on raltegravir (17/361, 5%) (p=0.003) (refer to section &lsquo;Resistance in vivo&rsquo; above for details).&nbsp;</p><p><em><u>Patients with prior treatment failure that included an integrase inhibitor (and integrase class resistance) </u></em></p><p>In the multicentre, open-label, single arm VIKING-3 study (ING112574), HIV-1 infected, ART-experienced adults with virological failure and current or historical evidence of raltegravir and/or elvitegravir resistance received Tivicay 50&nbsp;mg twice daily with the current failing background regimen for 7 days but with optimised background ART from Day 8.&nbsp; The study enrolled 183 patients, 133 with INI-resistance at Screening and 50 with only historical evidence of resistance (and not at Screening).&nbsp; Raltegravir/elvitegravir was part of the current failing regimen in 98/183 patients (part of prior failing therapies in the others).&nbsp; At baseline, median patient age was 48 years, 23% were female, 29% non-white, and 20% had hepatitis B and/or C co-infection.&nbsp; Median baseline CD4+ was 140&nbsp;cells/mm<sup>3</sup>, median duration of prior ART was 14 years, and 56% were CDC Class C.&nbsp; Subjects showed multiple class ART resistance at baseline: 79% had &ge;2 NRTI, 75% &ge;1 NNRTI, and 71% &ge;2 PI major mutations; 62% had non-R5 virus.</p><p>Mean change from baseline in HIV RNA at day 8 (primary endpoint) was -1.4log<sub>10</sub> copies/mL (95% CI -1.3 &ndash; -1.5log<sub>10</sub>, p&lt;0.001).&nbsp; Response was associated with baseline INI mutation pathway, as shown in Table 6. &nbsp;</p><p><strong>Table 7 </strong><strong>Virologic response (day 8) after 7 days of functional monotherapy, in patients with RAL/EVG as part of current failing regimen, VIKING 3</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Baseline parameters</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Dolutegravir 50&nbsp;mg BID</strong></p><p><strong>N=88<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>Mean (SD) Plasma HIV-1 RNA log<sub>10</sub> c/mL</p></td><td style="vertical-align:top"><p>Median</p></td></tr><tr><td style="vertical-align:top"><p>Derived IN mutation group at Baseline with ongoing RAL/EVG</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Primary mutation other than Q148H/K/R<sup>a</sup></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>-1.59 (0.47)</p></td><td style="vertical-align:top"><p>-1.64</p></td></tr><tr><td style="vertical-align:top"><p>Q148+1 secondary mutation<sup>b</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>-1.14 (0.61)</p></td><td style="vertical-align:top"><p>-1.08</p></td></tr><tr><td style="vertical-align:top"><p>Q148+&sup3;2 secondary mutations<sup>b</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-0.75 (0.84)</p></td><td style="vertical-align:top"><p>-0.45</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>*</sup>Of 98 on RAL/EVG as part of current failing regimen, 88 had detectable primary INI mutations at Baseline and a Day 8 Plasma HIV-1 RNA outcome for evaluation</p><p><sup>a</sup> Included primary IN resistance mutations N155H, Y143C/H/R, T66A, E92Q</p><p><sup>b</sup> Secondary mutations from G140A/C/S, E138A/K/T, L74I.</p></td></tr></thead></table><p>In patients without a primary mutation detected at baseline (N=60) (i.e. RAL/EVG not part of current failing therapy) there was a 1.63 log<sub>10</sub> reduction in viral load at day 8.</p><p>After the functional monotherapy phase, subjects had the opportunity to re-optimize their background regimen when possible.&nbsp; The overall response rate through 24 weeks of therapy, 69% (126/183), was generally sustained through 48 weeks with 116/183 (63%) of patients with HIV-1 RNA &lt;50c/mL (ITT-E, Snapshot algorithm). When excluding patients who stopped therapy for non-efficacy reasons, and those with major protocol deviations (incorrect dolutegravir dosing, intake of prohibited co-medication), namely, &ldquo;the Virological Outcome (VO)-population)&rdquo;, the corresponding response rates were 75% (120/161, week 24) and 69% (111/160, week 48).</p><p>The response was lower when the Q148-mutation was present at baseline, and in particular in the presence of &ge;2 secondary mutations, Table8.&nbsp; The overall susceptibility score (OSS) of the optimised background regimen (OBR) was not associated with Week 24 response, nor with the week 48 response.&nbsp;</p><p><strong>Table 8 Response by baseline Resistance, VIKING-3. VO Population (HIV-1 RNA &lt;50 c/mL, Snapshot algorithm)</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td colspan="5"><p><strong>Week 24 (N=161)</strong></p></td><td><p><strong>Week 48 (N=160)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Derived IN Mutation Group</strong></p></td><td style="vertical-align:bottom"><p><strong>OSS=0</strong></p></td><td style="vertical-align:bottom"><p><strong>OSS=1</strong></p></td><td style="vertical-align:bottom"><p><strong>OSS=2</strong></p></td><td style="vertical-align:bottom"><p><strong>OSS&gt;2</strong></p></td><td style="vertical-align:bottom"><p><strong>Total</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p></td></tr><tr><td style="vertical-align:top"><p>No primary IN mutation<sup>1</sup></p></td><td style="vertical-align:bottom"><p>2/2 (100%)</p></td><td style="vertical-align:bottom"><p>15/20 (75%)</p></td><td style="vertical-align:bottom"><p>19/21 (90%)</p></td><td style="vertical-align:bottom"><p>9/12 (75%)</p></td><td style="vertical-align:bottom"><p>45/55 (82%)</p></td><td><p>38/55 (69%)</p></td></tr><tr><td style="vertical-align:top"><p>Primary mutation other than Q148H/K/R<sup>2</sup></p></td><td style="vertical-align:bottom"><p>2/2 (100%)</p></td><td style="vertical-align:bottom"><p>20/20 (100%)</p></td><td style="vertical-align:bottom"><p>21/27 (78%)</p></td><td style="vertical-align:bottom"><p>8/10 (80%)</p></td><td style="vertical-align:bottom"><p>51/59 (86%)</p></td><td><p>50/58 (86%)</p></td></tr><tr><td style="vertical-align:top"><p>Q148 + 1 secondary mutation<sup>3</sup></p></td><td style="vertical-align:bottom"><p>2/2 (100%)</p></td><td style="vertical-align:bottom"><p>8/12 (67%)</p></td><td style="vertical-align:bottom"><p>10/17 (59%)</p></td><td style="vertical-align:bottom"><p>-</p></td><td style="vertical-align:bottom"><p>20/31 (65%)</p></td><td><p>19/31 (61%)</p></td></tr><tr><td style="vertical-align:top"><p>Q148 +&ge;2 secondary mutations<sup> 3</sup></p></td><td style="vertical-align:bottom"><p>1/2 (50%)</p></td><td style="vertical-align:bottom"><p>2/11 (18%)</p></td><td style="vertical-align:bottom"><p>1/3 (33%)</p></td><td style="vertical-align:bottom"><p>-</p></td><td style="vertical-align:bottom"><p>4/16 (25%)</p></td><td><p>4/16 (25%)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>1</sup> Historical or phenotypic evidence of INI resistance only.</p><p><sup>2</sup> N155H, Y143C/H/R, T66A, E92Q</p><p><sup>3</sup> G140A/C/S, E138A/K/T, L74I</p><p>OSS: combined genotypic and phenotypic resistance (Monogram Biosciences Net Assessment)</p></td></tr></tbody></table><p>The median change in CD4+ T cell count from baseline for VIKING-3 based on observed data was 61&nbsp;cells/mm<sup>3</sup> at Week 24 and 110&nbsp;cells/mm<sup>3</sup> at Week 48.&nbsp;</p><p>In the double blind, placebo controlled VIKING-4 study (ING116529), 30 HIV-1 infected, ART-experienced adults with primary genotypic resistance to INIs at Screening, were randomised to receive either dolutegravir 50&nbsp;mg twice daily or placebo with the current failing regimen for 7&nbsp;days followed by an open label phase with all subjects receiving dolutegravir. &nbsp;At baseline, median patient age was 49 years, 20% were female, 58% non-white, and 23% had hepatitis B and/or C co-infection.&nbsp; Median baseline CD4+ was 160 cells/mm<sup>3</sup>, median duration of prior ART was 13 years, and 63% were CDC Class C.&nbsp; Subjects showed multiple class ART resistance at baseline: 80% had &sup3;2 NRTI, 73% &sup3;1 NNRTI, and 67% &sup3;2 PI major mutations; 83% had non-R5 virus.&nbsp; Sixteen of 30 subjects (53%) harboured Q148 virus at baseline.&nbsp; The primary endpoint at Day 8 showed that dolutegravir 50&nbsp;mg twice daily was superior to placebo, with an adjusted mean treatment difference for the change from Baseline in Plasma HIV-1 RNA of -1.2 log<sub>10 </sub>copies/mL (95% CI -1.5 - -0.8log<sub>10</sub> copies/mL, p&lt;0.001). The day 8 responses in this placebo controlled study were fully in line with those seen in VIKING-3 (not placebo controlled), including by baseline integrase resistance categories. At week 48, 12/30 (40%) subjects had HIV-1 RNA &lt;50 copies/mL (ITT-E, Snapshot algorithm).</p><p>In a combined analysis of VIKING-3 and VIKING-4 (n=186, VO population), the proportion of subjects with HIV RNA &lt;50 copies/mL at Week 48 was 123/186 (66%).&nbsp; The proportion of subjects with HIV RNA &lt;50 copies/mL was 96/126 (76%) for No Q148 mutations, 22/41 (54%) for Q148+1 and 5/19 (26%) for Q148+&sup3;2 secondary mutations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dolutegravir pharmacokinetics are similar between healthy and HIV-infected subjects. The PK variability of dolutegravir is low to moderate. In Phase I studies in healthy subjects, between-subject CVb% for AUC and C<sub>max</sub> ranged from ~20 to 40% and Ct from 30 to 65% across studies.&nbsp; The between-subject PK variability of dolutegravir was higher in HIV-infected subjects than healthy subjects. Within-subject variability (CVw%) is lower than between-subject variability.</p><p>&nbsp;</p><p><u>Absorption </u></p><p>Dolutegravir is rapidly absorbed following oral administration, with median T<sub>max</sub> at 2 to 3 hours post dose for tablet formulation.</p><p>Food increased the extent and slowed the rate of absorption of dolutegravir.&nbsp; Bioavailability of dolutegravir depends on meal content: low, moderate, and high fat meals increased dolutegravir AUC<sub>(0-</sub><sub>&yen;</sub><sub>)</sub> by 33%, 41%, and 66%, increased C<sub>max</sub> by 46%, 52%, and 67%, prolonged T<sub>max</sub> to 3, 4, and 5 hours from 2 hours under fasted conditions, respectively for the film-coated tablet. These increases may be clinically relevant in the presence of certain integrase class resistance. Therefore, Tivicay is recommended to be taken with food by patients infected with HIV with integrase class resistance (see section 4.2).</p><p>The absolute bioavailability of dolutegravir has not been established.&nbsp;</p><p>&nbsp;</p><p><u>Distribution </u></p><p>Dolutegravir is highly bound (&gt;99%) to human plasma proteins based on <em>in vitro</em> data.&nbsp; The apparent volume of distribution is 17&nbsp;L to 20&nbsp;L in HIV-infected patients, based on a population pharmacokinetic analysis.&nbsp; Binding of dolutegravir to plasma proteins is independent of dolutegravir concentration.&nbsp; Total blood and plasma drug‑related radioactivity concentration ratios averaged between 0.441 to 0.535, indicating minimal association of radioactivity with blood cellular components. The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin (&lt;35 g/L) as seen in subjects with moderate hepatic impairment.</p><p>Dolutegravir is present in cerebrospinal fluid (CSF).&nbsp; In 13 treatment-na&iuml;ve subjects on a stable dolutegravir plus abacavir/lamivudine regimen, dolutegravir concentration in CSF averaged 18&nbsp;ng/mL (comparable to unbound plasma concentration, and above the IC50).&nbsp;</p><p>Dolutegravir is present in the female and male genital tract.&nbsp; AUC in cervicovaginal fluid, cervical tissue and vaginal tissue were 6-10% of those in corresponding plasma at steady state. AUC in semen was 7% and 17% in rectal tissue of those in corresponding plasma at steady state.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Dolutegravir is primarily metabolized through glucuronidation via UGT1A1 with a minor CYP3A component.&nbsp; Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged active substance is low (&lt; 1% of the dose).&nbsp; Fifty-three percent of total oral dose is excreted unchanged in the faeces. It is unknown if all or part of this is due to unabsorbed active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form the parent compound in the gut lumen.&nbsp; Thirty-two percent of the total oral dose is excreted in the urine, represented by ether glucuronide of dolutegravir (18.9% of total dose), N-dealkylation metabolite (3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose).</p><p>&nbsp;</p><p><u>Drug interactions</u></p><p><em>In vitro</em>, dolutegravir demonstrated no direct, or weak inhibition (IC50&gt;50 &mu;M) of the enzymes cytochrome P<sub>450</sub> (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 CYP3A, uridine diphosphate glucuronosyl transferase (UGT)1A1 or UGT2B7, or the transporters Pgp, BCRP, BSEP, OATP1B1, OATP1B3, OCT1, MATE2-K, MRP2 or MRP4. <em>In vitro</em>, dolutegravir did not induce CYP1A2, CYP2B6 or CYP3A4. Based on this data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of major enzymes or transporters (see section 4.5).</p><p><em>In vitro</em>, dolutegravir was not a substrate of human OATP 1B1, OATP 1B3 or OCT 1.</p><p>&nbsp;</p><p><u>Elimination </u></p><p>Dolutegravir has a terminal half-life of ~14&nbsp;hours.&nbsp; The apparent oral clearance (CL/F) is approximately 1L/hr in HIV-infected patients based on a population pharmacokinetic analysis.</p><p>&nbsp;</p><p><u>Linearity/non-linearity </u></p><p>The linearity of dolutegravir pharmacokinetics is dependent on dose and formulation. Following oral administration of film-coated tablet formulations, in general, dolutegravir exhibited nonlinear pharmacokinetics with less than dose-proportional increases in plasma exposure from 2 to 100&nbsp;mg; however increase in dolutegravir exposure appears dose proportional from 25&nbsp;mg to 50&nbsp;mg for the film-coated tablet formulation. With 50&nbsp;mg film-coated tablet twice daily, the exposure over 24 hours was approximately doubled compared to 50&nbsp;mg film-coated tablet once daily.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship(s)</u></p><p>In a randomized, dose-ranging trial, HIV‑1&ndash;infected subjects treated with dolutegravir monotherapy (ING111521) demonstrated rapid and dose-dependent antiviral activity, with mean decline in HIV-1 RNA of 2.5&nbsp;log<sub>10</sub> at day 11 for 50&nbsp;mg dose. This antiviral response was maintained for 3 to 4 days after the last dose in the 50&nbsp;mg film-coated tablet group.&nbsp;</p><p>PK/PD modelling using pooled data from clinical studies in integrase resistant patients suggest that increasing the dose from 50&nbsp;mg film-coated tablet twice daily to 100&nbsp;mg film-coated tablet twice daily may increase the effectiveness of dolutegravir in patients with integrase resistance and limited treatment options due to advanced multi class resistance. The proportion of responders (HIV-1 RNA &lt;50 c/mL) at week 24 was predicted to increase around 4-18% in the subjects with Q148 + &sup3;2 secondary mutations from G140A/C/S, E138A/K/T, L74I. Although these simulated results have not been confirmed in clinical trials, this high dose may be considered in the presence of the Q148 + &sup3;2 secondary mutations from G140A/C/S, E138A/K/T, L74I in patients with overall limited treatment options due to advanced multi class resistance. There is no clinical data on the safety or efficacy of the 100&nbsp;mg film-coated tablet twice daily dose. Co-treatment with atazanavir increases the exposure of dolutegravir markedly, and should not be used in combination with this high dose, since safety with the resulting dolutegravir exposure has not been established.</p><p>&nbsp;</p><p><u>Special patient populations</u></p><p><em>Adolescents</em></p><p>The pharmacokinetics of dolutegravir in 10 antiretroviral treatment-experienced HIV-1 infected adolescents (12 to &lt;18&nbsp;years of age) showed that Tivicay 50&nbsp;mg once daily oral dosage resulted in dolutegravir exposure comparable to that observed in adults who received Tivicay 50&nbsp;mg orally once daily.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Population pharmacokinetic analysis of dolutegravir using data in HIV-1 infected adults showed that there was no clinically relevant effect of age on dolutegravir exposure.</p><p>Pharmacokinetic data for dolutegravir in subjects &gt;65 years of age are limited.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Renal clearance of unchanged active substance is a minor pathway of elimination for dolutegravir. A study of the pharmacokinetics of a single 50 mg dose of dolutegravir film-coated tablets was performed in subjects with severe renal impairment (CLcr &lt;30&nbsp;mL/min) and matched healthy controls. The exposure to dolutegravir was decreased by approximately 40% in subjects with severe renal impairment. The mechanism for the decrease is unknown. No dosage adjustment is considered necessary for patients with renal impairment. Tivicay has not been studied in patients on dialysis.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Dolutegravir is primarily metabolized and eliminated by the liver. A single 50&nbsp;mg dose of dolutegravir film-coated tablets was administered to 8 subjects with moderate hepatic impairment (Child-Pugh class B) and to 8 matched healthy adult controls. While the total dolutegravir concentration in plasma was similar, a 1.5- to 2-fold increase in unbound exposure to dolutegravir was observed in subjects with moderate hepatic impairment compared to healthy controls. No dosage adjustment is considered necessary for patients with mild to moderate hepatic impairment. The effect of severe hepatic impairment on the pharmacokinetics of Tivicay has not been studied.</p><p>&nbsp;</p><p><em>Polymorphisms in drug metabolising enzymes</em></p><p>There is no evidence that common polymorphisms in drug metabolising enzymes alter dolutegravir pharmacokinetics to a clinically meaningful extent. In a meta-analysis using pharmacogenomics samples collected in clinical studies in healthy subjects, subjects with UGT1A1 (n=7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n=41).</p><p>&nbsp;</p><p><em>Gender</em></p><p>Population PK analyses using pooled pharmacokinetic data from Phase IIb and Phase III adult trials revealed no clinically relevant effect of gender on the exposure of dolutegravir.</p><p>&nbsp;</p><p><em>Race </em></p><p>Population PK analyses using pooled pharmacokinetic data from Phase IIb and Phase III adult trials revealed no clinically relevant effect of race on the exposure of dolutegravir. The pharmacokinetics of dolutegravir following single dose oral administration to Japanese subjects appear similar to observed parameters in Western (US) subjects.</p><p>&nbsp;</p><p><em>Co-infection with Hepatitis B or C </em></p><p>Population pharmacokinetic analysis indicated that hepatitis C virus co-infection had no clinically relevant effect on the exposure to dolutegravir. There are limited data on subjects with hepatitis B co-infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dolutegravir was not mutagenic or clastogenic using <em>in vitro</em> tests in bacteria and cultured mammalian cells, and an <em>in vivo</em> rodent micronucleus assay.&nbsp; Dolutegravir was not carcinogenic in long term studies in the mouse and rat.</p><p>Dolutegravir did not affect male or female fertility in rats at doses up to 1000&nbsp;mg/kg/day, the highest dose tested (24 times the 50&nbsp;mg twice daily human clinical exposure based on AUC).&nbsp;</p><p>In reproductive toxicity studies in animals, dolutegravir was shown to cross the placenta.</p><p>Oral administration of dolutegravir to pregnant rats at doses up to 1000&nbsp;mg/kg daily from days 6 to 17 of gestation did not elicit maternal toxicity, developmental toxicity or teratogenicity (27 times the 50&nbsp;mg twice daily human clinical exposure based on AUC).</p><p>Oral administration of dolutegravir to pregnant rabbits at doses up to 1000&nbsp;mg/kg daily from days 6 to 18 of gestation did not elicit developmental toxicity or teratogenicity (0.40 times the 50&nbsp;mg twice daily human clinical exposure based on AUC).&nbsp; In rabbits, maternal toxicity (decreased food consumption, scant/no faeces/urine, suppressed body weight gain) was observed at 1000&nbsp;mg/kg (0.40 times the 50&nbsp;mg twice daily human clinical exposure based on AUC).&nbsp;</p><p>In a juvenile toxicity study in rats, dolutegravir administration resulted in two preweanling deaths at 75&nbsp;mg/kg/day.&nbsp; Over the preweaning treatment period, mean body weight gain was decreased in this group and the decrease persisted throughout the entire study for females during the postweaning period.&nbsp; The systemic exposure at this dose (based on AUC) to dolutegravir was ~17-20-fold higher than humans at the recommended pediatric exposure.&nbsp; There were no new target organs identified in juveniles compared to adults. &nbsp;In the rat pre/post-natal development study, decreased body weight of the developing offspring was observed during lactation at a maternally toxic dose (approximately 27 times human exposure at the maximum recommended human dose).</p><p>The effect of prolonged daily treatment with high doses of dolutegravir has been evaluated in repeat oral dose toxicity studies in rats (up to 26 weeks) and in monkeys (up to 38 weeks).&nbsp; The primary effect of dolutegravir was gastrointestinal intolerance or irritation in rats and monkeys at doses that produce systemic exposures approximately 21 and 0.82 times the 50&nbsp;mg twice daily human clinical exposure based on AUC, respectively.&nbsp; Because gastrointestinal (GI) intolerance is considered to be due to local active substance administration, mg/kg or mg/m<sup>2</sup> metrics are appropriate determinates of safety cover for this toxicity.&nbsp; GI intolerance in monkeys occurred at 15 times the human mg/kg equivalent dose (based on a 50&nbsp;kg human), and 5 times the human mg/m<sup>2</sup> equivalent dose for a clinical dose of 50&nbsp;mg twice daily.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>D-Mannitol<br />Microcrystalline Cellulose<br />Povidone K29/32<br />Sodium Starch Glycolate<br />Sodium Stearyl Fumarate</p><p><u>Tablet coating</u></p><p>Poly (vinyl alcohol) partially hydrolyzed</p><p>Titanium dioxide</p><p>Macrogol/PEG</p><p>Talc</p><p>Iron oxide yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from moisture. Keep the bottle tightly closed.</p><p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE (high density polyethylene) bottles.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p><em>TIVICAY</em> is trademark owned by or licensed to the ViiV Healthcare group of companies.</p><p>&copy; 2024 ViiV Healthcare group of companies, all rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Delpharm Poznań Spółka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland
	
Marketing Authorization Holder
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia
*member of the GlaxoSmithKline group of companie
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VERSION NUMBER: UKv31
DATE OF REVISION OF THE TEXT: 15 June 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>